Podcasts about GIP

Most people are taking peptide therapy completely wrong, and Dr. Justin Hogan, a functional medicine physician, joins host Shawn Lynch to explain why. Together they break down BPC 157, TB 500 and GLP 1 weight loss drugs and what actually works.The conversation goes deep into how peptides actually work inside the body, covering growth hormone secretagogues like CJC 1295, Ipamorelin and Tesamorelin, recovery peptides like BPC 157 and TB 500, longevity focused compounds like Epithalon and NAD, and the real science behind GLP 1 and GIP medications such as semaglutide and tirzepatide. Shawn and Dr. Hogan unpack why nutrition, hormone optimization and gut health have to come first, how to avoid wasting money on unregulated research peptides, and the exact questions you should ask any provider before starting a protocol. Whether you are chasing weight loss, faster recovery, better sleep or long term longevity, this episode hands you a real framework instead of Instagram hype.If you are ready to take control of your health and performance, subscribe to Official Success Formula for more episodes like this one, and listen to the full conversation on the Success Formula Podcast for even more detail you will not want to miss. This is the kind of insight that separates people who guess from people who actually get results.Instagram- https://www.instagram.com/justinhoganmd/Instagram- https://www.instagram.com/officialsuccessrx/Tune in every Tuesday at 10 AM for another inspiring success story, along with the proven formula to help you achieve your own goals. Don't miss out on the insights that could change your life!Buzzsprout- https://successformulapodcast.buzzsprout.com/Spotify - https://open.spotify.com/show/7aRe06pXIq6yq8GQf62NBMAmazon Music - https://music.amazon.com/podcasts/1393b77c-626a-4a53-bdd5-43ce3b1aa15b/success-formula-podcastApple Podcast- https://podcasts.apple.com/gb/podcast/success-formula-podcast/id1748704615Our Social Media:Youtube: https://www.youtube.com/@OfficialSuccessFormulaInstagram: https://www.instagram.com/officialsuccessformula/Twitter: https://x.com/_SuccessFormula/Tiktok: https://www.tiktok.com/@officialsuccessformula

ZOE nutritionist Dr. Federica Amati explains why basal metabolic rate barely changes in perimenopause, but postprandial metabolism does, glucose, fat, insulin, and inflammation stay elevated longer after meals, partly via gut microbiome shifts. She unpacks why "thin" can mask sarcopenic obesity, why calorie labels carry ~20% error, why a nutrient-dense breakfast curbs cravings, and why a 70,000-woman ZOE study saw a 35% symptom drop from diet changes alone. WHAT YOU'LL LEARN - Why basal metabolic rate isn't the problem in perimenopause, but postprandial metabolism is - What's actually driving new midsection fat storage as estrogen declines - Why calorie counting fails as a long-term strategy, from label error to the food matrix effect - How satiety hormones like GLP-1, PYY, and GIP shift after menopause, and why breakfast is the highest-leverage meal of the day - Why looking thin doesn't mean you're metabolically healthy, and what sarcopenic obesity reveals about muscle as an organ - What HRT actually changes about your metabolism, muscle mass, and visceral fat, and what it doesn't - How a 70,000-woman study found a 35% drop in menopause symptoms from diet changes alone, and why brain fog improved most TIMESTAMPS 00:00 – Intro 08:00 – Inside ZOE's Age-Matched Study: Why Postprandial Metabolism Shifts After Menopause 16:00 – Same Meal, Different Response: Satiety Hormones, Carb Cravings & Why Under-Eating Backfires 25:00 – Weight Set Point, Calorie Quality & the Sarcopenic Obesity Trap 34:00 – Why Calorie Counting Fails: Label Error, Nutrient Absorption & the Food Matrix Effect 40:00 – The 70,000-Woman Study: A 35% Symptom Drop From Diet Alone (and Why Breakfast Matters Most) 45:00 – What HRT Actually Does (and Doesn't Do) for Metabolism, Muscle & Visceral Fat 52:00 – Building Your Metabolic Buffer Before Menopause in an Obesogenic World VALUABLE RESOURCES Dr Federica Amati's new book: The Appetite ResetHow appetite really works, what GLP-1 medications are actually doing in the body, and how to eat to support your natural appetite signals, on medication or not.

Semaglutide, tirzepatide and retatrutide are often spoken about as though they are simply different versions of the same thing. They are not—and Kim Constable's personal experience with each one was very different. In this episode, Kim moves beyond receptor science and shares what exploring all three compounds was actually like for her: the benefits she noticed, the side effects she experienced, the results that surprised her and which option she personally preferred. Kim's interest in GLP-1s originally extended far beyond weight loss. As she moved further into menopause, she was struggling with persistent gluteal tendinopathy, joint pain, digestive discomfort, bloating, morning headaches, brain fog, broken sleep and repeated nighttime bathroom trips. Foods she had eaten comfortably for years—including beans, lentils and cruciferous vegetables—had become increasingly difficult to tolerate. After hearing GLP-1s discussed in relation to inflammation, digestion, sleep and metabolic health, Kim began exploring semaglutide. She later tried tirzepatide and retatrutide, allowing her to compare her personal response to all three. The compounds target different combinations of pathways: • Semaglutide primarily targets GLP-1 • Tirzepatide targets GLP-1 and GIP • Retatrutide targets GLP-1, GIP and glucagon Kim explains why those differences matter and why a compound that feels transformative for one person may feel far less effective—or create more unwanted effects—for another. Inside this episode: • Why Kim first became interested in GLP-1s during menopause • The difference between semaglutide, tirzepatide and retatrutide • Why more receptor activity does not automatically mean better results • Kim's personal experiences with appetite and food noise • The differences she noticed in inflammation and physical pain • Changes she observed in digestion, headaches, brain fog and sleep • How each experience affected fat loss and weight maintenance • Why she initially felt hesitant to admit that easier fat loss appealed to her • The judgment surrounding GLP use • Fatigue, headaches and digestive slowing • An unexpected herpes flare-up pattern Kim noticed while taking semaglutide • Why anecdotal observations do not prove clinical causation • The benefits that felt meaningful to Kim and the effects that did not • Which of the three she personally preferred • Why another person's experience or dose should never become your protocol This episode is not intended to tell listeners which compound they should choose. It is a candid account of Kim's individual experience with three different compounds and why she believes the decision is far more nuanced than simply asking which one is “strongest.” This episode contains candid discussion of genital herpes, digestive symptoms and medication side effects. Kim's experience is personal. Nothing discussed should be treated as proof that another person will experience the same benefits, risks or side effects. This podcast is for educational and informational purposes only. Kim is not a doctor or licensed medical practitioner. Nothing in this episode should be interpreted as medical advice, a diagnosis, prescribing guidance or instructions for purchasing, reconstituting, dosing or administering any compound. Always consult an appropriately qualified healthcare professional before beginning, stopping or changing any medication or treatment. Some compounds discussed may be prescription medicines or investigational products depending on jurisdiction and current regulatory status. ✨ Follow Kim Constable online for more real talk and daily motivation:

What if the way we think about our weight started long before we ever chose to think about it at all?And what if we're having the wrong types of conversations about GLP-1s?Ashley Koff is a registered dietitian, weight health expert, and founder of the Better Nutrition Program. Her understanding of weight is deeply personal, too—and she's spent her career building the framework she wishes had existed for her.In this conversation, Ashley unpacks the critical difference between weight loss and weight health, what GLP-1 and GIP hormones actually do in the body, and why optimizing your hormones matters whether or not you ever touch the medication.But before any of that, she shares a story she kept to herself for decades—one that will resonate with anyone who has ever felt like their body was a problem that needed a solution.What You Will Learn[00:10:00] Ashley's bully moment at age eight — and 40 years of carrying it[00:15:00] How disempowerment leads to risky behaviors — the research behind it[00:20:00] When Ashley's body started feeling like it was working against her[00:30:30] The bar, the stranger, and Ashley's life-changing rock bottom[00:36:30] What introduced her to GLP-1 hormones in 2004[00:49:30] What GLP-1 and GIP actually do — beyond blood sugar[00:53:30] Right order matters — digestion, hydration, and movement first[01:08:30] What "your best shot" actually means beyond the medicationResources MentionedYour Best Shot by Ashley Koff, RDBetter Nutrition Program Let's Connect!Ashley KoffInstagram | LinkedInChandler StroudWebsite | LinkedIn | InstagramHappiness Academy is now Healing Heroines, a signature space for women who are ready to feel more grounded, more peaceful, and more aligned — inside and out. Download a complimentary Healing Roadmap to discover our Past, Present, and Possible framework.Want personalized guidance for your healing journey? Book a call with Chandler!Mixing and editing provided by Next Day Podcast.Text message us questions, requests, or comments!

GLP-1 medications are everywhere right now, and not just because people are losing weight. We're starting to see something far more interesting for addiction medicine: semaglutide may reduce alcohol cravings and heavy drinking, and early data hints it could influence other compulsive behaviors too. I recorded this talk after giving it as a lecture to my colleagues, and it's one I've wanted to share for a long time because the science is moving fast and the clinical questions are piling up.We walk through what GLP-1 drugs actually are, how gut hormones like GLP-1 and GIP shape appetite, digestion, and glycaemic control, and why side effects like nausea and bloating are so common. I also clear up the most confusing practical point patients run into: Ozempic versus Wegovy and Mounjaro versus Zepbound are often the same molecules labelled for different indications, and insurance coverage usually follows those rules.Then we get into the addiction evidence. I review three recent randomized controlled trials from 2025 to 2026 studying semaglutide for alcohol use disorder, including injectable and oral versions. The results aren't magic, but they're meaningful: fewer drinks on drinking days, fewer heavy drinking days, and lower craving scores compared with placebo, plus secondary findings that raise new research questions about nicotine and cannabis. Finally, I share two de-identified patient cases that show why GLP-1s can be a game-changer for some people and only a small nudge for others, especially when depression, grief, anxiety, or PTSD is the true engine behind drinking.If this helped you think differently about recovery tools, subscribe, share the show with a colleague or friend, and leave a review so more people can find it.To contact Dr. Grover: ammadeeasy@fastmail.com

People often think of weight loss drugs like GLP-1 and related agonists (e.g., Wegovy and Mounjaro) as “medications”--which they are, but they work because they mimic our own natural gut hormones to lower blood sugar, slow digestion, blunt appetite, and ultimately reduce weight. In that way, they're weight health hormone replacement therapies much like estrogen and progesterone are sex hormone replacement therapies, says this week's guest best-selling dietitian Ashley Koff, RD. We dig into weight-health hormones (GLP-1, GIP, PYY, CCK) that regulate appetite and metabolism, why digestion and hydration have to be optimized before nutrition even enters the picture, and how GLP-1 medications and hormone replacement therapy can work together in perimenopause and menopause. Plus: Ashley's own story of Everesting Mount Rainier at 52.Ashley Koff, RD, is the USA Today bestselling author of Your Best Shot (HarperOne). With more than 25 years as a practitioner and educator, she's helped redefine the conversation from weight loss to weight health — a science-based framework focused on metabolic function and hormonal regulation. She's been named one of CNN's Top 100 Health Makers and "Hollywood's Leading Dietitian" by InStyle. You can learn more about her and her work at her practice, The Better Nutrition Program.FeistyFit Info: https://livefeisty.com/training/running/feistyfitfall/Join us at Feisty Fest September 18-20, 2026: https://livefeisty.com/events/feisty-fest/Women's Mechanic Camp in Tucson: https://livefeisty.com/events/bike-mechanic-school-tucson/Courses and Coaching: https://livefeisty.com/courses/Sign up for our FREE Feisty 40+ newsletter: https://livefeisty.com/newsletters/feisty-40/Follow Us on Instagram:Feisty Menopause: @feistymenopauseHit Play Not Pause Facebook Group: https://www.facebook.com/groups/807943973376099Support our Partners:Midi Health: You Deserve to Feel Great. Book your virtual visit today at https://www.joinmidi.com/Previnex: Get 15% off your order with code HITPLAY at https://www.previnex.com/ Wahoo: Use the code FEISTY2026 to get a free Headwind Smart Fan (value $300) with the purchase of a Wahoo KICKR RUN at https://shorturl.at/WVhdr

This isn't an anti-GLP-1 episode. It's an anti-“here's your injection, see you in six months” episode. In this episode of Root Cause Radio, we break down how GLP-1 medications work, including semaglutide, the dual GLP-1/GIP agonist tirzepatide, and the investigational triple agonist retatrutide. We explain how these medications truly work (and how some may work better than others), and how they influence appetite, fullness, blood sugar, gastric emptying, fat metabolism, and energy expenditure.We also explore the parts of GLP-1 use that are too often ignored:• Undereating, nutrient deficiencies, and inadequate protein intake• Muscle loss and changes in body composition• Nausea, constipation, reflux, bloating, and impaired gut motility• Potential consequences for women's hormones, menstrual cycles, and fertility• Gallbladder, pancreatic, kidney, and dehydration concerns• Reduced pleasure, motivation, and possible anhedonia• Metabolic adaptation and weight regain after stopping• The emerging conversation around low-dose or “microdosed” GLP-1 use for conditions such as endometriosis, MCAS, and autoimmune diseaseMost importantly, we discuss what responsible GLP-1 care should actually look like: adequate calories and protein, resistance training, micronutrient monitoring, proactive GI support, individualized dosing, body-composition assessment, and a transition plan that begins before the medication is stopped.GLP-1 medications can be valuable tools- let's know what they really do, how they work, and how do use them responsibly. My Website & Work with Me: Instagram: ⁠⁠⁠⁠⁠www.instagram.com/faithandfit⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.upliftfitnutrition.com⁠⁠⁠⁠⁠Email for coaching & phone consults: laceydunn@upliftfitnutrition.com & fitandfaith@gmail.comOrder my book ⁠⁠"The Women's Guide to Hormonal Harmony" ⁠⁠on amazon! Anya Rosen's info:Website: https://birchwell.clinic/aboutInstagram: https://www.instagram.com/anyaargosh/Email: anya@birchwell.clinic

What if the goal is not to become smaller, but to help your body work better? In this episode of Doing Divorce Different, Lesa Koski talks with registered dietitian and weight-health expert Ashley Koff, RD, author of Your Best Shot: The Personalized System for Optimal Weight Health—GLP-1 Shot or Not.Ashley reframes GLP-1 weight loss by explaining why weight is a signal—not a moral judgment—and why total weight can include bone, muscle, fat, and water. She shares how naturally occurring GLP-1 and related hormones are connected with appetite, satiety, blood sugar, digestion, and other aspects of metabolic health.You will hear a nuanced conversation about when GLP-1 medication may be one helpful tool, why it is never the entire plan, and what to consider if you experience side effects or prefer a non-medication approach. Ashley also discusses food noise, gut health, hydration, nourishment, strength, sleep, and the often-missed role of rest and recovery.For anyone navigating divorce, menopause, illness, or another major life transition, this episode offers a more compassionate way to approach GLP-1 weight loss and overall well-being. Instead of chasing a number on the scale, Ashley encourages listeners to protect muscle, bone, energy, and the resources needed to live their purpose.If you are curious about GLP-1 weight loss, struggling with food noise, or wondering why a popular plan has not worked for your body, listen before making your next move. Save this episode, share it with a friend, and bring your questions to a qualified member of your health-care team.This episode is educational and is not medical advice. Consult qualified health professionals before starting, stopping, or changing medication, supplements, nutrition, or exercise.Timestamps (in parentheses):(00:00) Introduction to weight health with Ashley Koff, RD(07:00) Why weight is a signal—not a judgment(10:00) GLP-1 medications are a tool, not a magic solution(12:40) GLP-1, GIP, muscle, and bone-health nuance(17:05) What everyone needs—with a GLP-1 medication or without one(21:30) How to evaluate whether medication may fit your needs(30:15) Your Best Shot and the foundations of digestion and hydration(34:50) Why drinking more water is not the whole hydration story(38:30) Food noise and ways to support the body without medication(43:35) Why “weight loss” may include losses you do not want(49:15) Rest, recovery, and caring for yourself during divorce(52:10) Giving yourself the best shot at your next chapter(54:05) Closing thoughts and where to learn moreTimestamp note: These timestamps are based on the supplied transcript and should be checked against the final edited audio or video before publishing.Key Takeaways:Weight health includes bone, muscle, fat, water, energy, digestion, and other signals—not only the number on the scale.GLP-1 medications may be useful for some people, but they do not replace individualized nutrition, hydration, movement, sleep, monitoring, and recovery.“Weight loss” can include unwanted muscle, bone, water, hair, and energy loss; a better plan defines the specific outcome being pursued.Food noise and medication side effects deserve personalized assessment rather than shame, guesswork, or one-size-fits-all advice.During divorce or another demanding transition, rest and recovery are legitimate parts of caring for your health.Guest Bio:Ashley Koff, RD, is the USA Today bestselling author of Your Best Shot (HarperOne), founder of The Better Nutrition Program (BNP), and a pioneering voice behind the emerging weight health movement. A practitioner and thought-leader with more than 25 years of experience, Ashley has helped redefine how we approach weight, shifting the conversation from weight loss to weight health, a science-based framework focused on metabolic function, hormonal regulation, and sustainable outcomes. Through her work with patients, clinicians, leading brands and companies, and health organizations, Ashley has developed practical systems that translate complex nutrition science into personalized strategies people can actually implement. In Your Best Shot, Ashley introduces the concept of weight-health hormones, GLP-1, GIP, CCK, and PYY, as key regulators of weight health. The book presents the first functional assessment framework for these hormones along with a personalized optimization approach designed to support weight health whether using GLP-1 medications or not (“shot or not”). A trusted expert featured across major media and a sought-after educator for health professionals, Ashley has been recognized as one of CNN's Top 100 Health Makers and named “Hollywood's Leading Dietitian” by InStyle. Through her clinical work, educational programs, and writing, Ashley continues to lead a growing movement toward better, not perfect, nutrition that supports long-term metabolic and weight health.Resource Links:Your Best Shot by Ashley Koff, RDAshley Koff and The Better Nutrition ProgramOsteoStrong Minnesota—Lesa Koski affiliate referralSoberlink family-law resources—Lesa Koski affiliate referralhttps://www.instagram.com/ashleykoffapproved/?hl=en, https://www.linkedin.com/in/ashley-koff/, https://substack.com/@ashleykoffrd?r=3fuq67&utm_campaign=profile&utm_medium=profile-pageAffiliate disclosure: Lesa may receive compensation if you make a purchase through an affiliate link, at no additional cost to you.Tags/Keywords:GLP-1 weight loss, weight health, Ashley Koff RD, Your Best Shot book, GLP-1 medications, GLP-1 shot or not, gut health, food noise, metabolic health, women's health, nutrition during divorce, divorce wellness, muscle loss, bone health, strength training, rest and recovery, hydration, semaglutide, tirzepatide, appetite hormones, personalized nutrition, healthy weight management, perimenopause health, menopause nutrition, Doing Divorce Different, Lesa Koski

Ever wonder why you still feel exhausted even after a "full night's sleep"? The answer might be sitting in your medicine cabinet or in a disorder you've never been tested for.   In this episode, Dr. V sits down with Dr. Meredith Broderick, a triple board-certified neurologist and sleep medicine physician (one of only four in the world boarded in neurology, sleep medicine, AND behavioral sleep medicine) and founder of Sound Sleep Guru in Seattle. Together they break down why modern life has broken our sleep, why common sleep meds may be doing more harm than good, and what actually works to restore deep, restorative rest.   In this episode, we cover: Why sleep apnea is the most undiagnosed sleep disorder in the world How sleeping pills like Ambien and Zolpidem block your brain's glymphatic "cleaning" system The link between anticholinergic sleep meds and dementia risk Why alcohol, benzodiazepines, and cannabis wreck your sleep architecture How artificial light and modern life decoupled us from our circadian rhythm New GLP-1/GIP medications now FDA-approved for sleep apnea How Ozlo Sleepbuds use audio and biometrics to improve sleep Rapid-fire scores on melatonin, naps, morning sunlight, exercise timing, and temperature How to build a simple, effective wind-down routine Where to actually go for help with a sleep problem Explore Sound Sleep Guru: https://soundsleepguru.com/ Follow Doctor V https://instagram.com/doctorvmd Get the #1 bestselling book Thrive State https://thrivestatebook.com Download the FREE Longevity & Human Potential Starter Guide https://thrivestatestarter.com Join the Thrive State Membership https://mythrivestate.com/join  

Wylecz Insulinooporność!---Witajcie w kolejnym odcinku! Dzisiaj odpowiadamy na pytania o popularne zastrzyki na odchudzanie, wyjaśniamy zasady działania przewodu pokarmowego oraz analizujemy, jak naturalnie stymulować wydzielanie hormonów odpowiedzialnych za kontrolę apetytu. Z tego odcinka dowiesz się:Jak zbudowany jest przewód pokarmowy – od żołądka po jelito grube – oraz jaką rolę w procesie trawienia i chłonięcia składników odżywczych odgrywają kosmki jelitowe i komórki enteroendokrynne.W jaki sposób komórki L i K reagują na odżywcze posiłki i jak białka oraz tłuszcze stymulują naturalny wyrzut hormonów GLP-1 i GIP bez konieczności sięgania po farmakoterapię.Co na temat diety wysokobiałkowej i remisji stanu przedcukrzycowego mówią aktualne badania naukowe oraz dlaczego zmiana stylu odżywiania pozwala zresetować mechanizmy sytości i wycofać insulinooporność.Zdrowie zaczyna się od wiedzy! Włącz odcinek, przejmij odpowiedzialność za własny metabolizm i dowiedz się, jak świadomie odzyskiwać kontrolę nad swoim ciałem.Wskakuj na naszą stronę https://braciarodzen.pl/wakacje-z-bracmi-rodzen/ i zapisz się do tej akcji czeka na Ciebie mnóstwo wiedzy slajdy oraz praktyczne prezenty. Słuchajcie nas regularnie we wtorki, środy i czwartki o 21:00. Subskrybujcie podcast, zostawcie łapkę w górę, udostępniajcie i do zobaczenia w kolejnym odcinku!---Akcja Wylecz Insulinooporność! -  pod patronatem: Polskiego Towarzystwa Leczenia Insulinooporności! https://ptli.pl/ ====Ważne: Nasz podcast może być emitowany z opóźnieniem w stosunku do odcinków na żywo. Promocje i informacje o wydarzeniach mogą być nieaktualne. Aktualne informacje znajdziesz na naszej stronie lub innych kanałach – linki poniżej.====Jeśli to, co robimy, jest dla Ciebie wartościowe, spraw, aby inni mogli to odkryć – udostępnij ten podcast i zostaw ocenę! ⭐⭐⭐⭐⭐ Twoja opinia ma znaczenie i pomaga nam docierać do kolejnych osób, które potrzebują tej wiedzy. Dziękujemy za Twoje wsparcie!Dołącz do NIEZALEŻNIE MYŚLĄCEJ i pięknie żyjącej społeczności

Hormones and peptides are some of the most talked-about therapies in healthcare today. But how do you know if they're right for your body? In this episode of Taste Life Nutrition Radio & Podcast, we're cutting through the noise and hype to have an honest conversation about hormones, GLP-1s, therapeutic peptides, and what it really means to support your body with wisdom and discernment. I also share my own journey through perimenopause and the frustration of watching my body change despite doing "all the right things." Learning to partner with my body instead of fighting it changed everything. These therapies aren't miracle solutions. They're tools, and the key is knowing whether they're the right tools for you. At its heart, this conversation is about building Health Intelligence. Your body is remarkably intelligent and always communicating. When we stop silencing symptoms and start listening, we can make confident, informed decisions that build the health giving us the capacity to fully taste life. ⏱️ KEY MOMENTS

On this episode of Diabetes Connections In the news… Sanofi acknowledges an insulin shortage, a new oral therapy for type 1 moves along in research, could there be an actual, accurate, non-invasive CGM in the works, ADA conflict continues and a new documentary about Girl Scout cookies shines a spotlight on T1D. Don't miss our upcoming events! Moms' Night Out in Detroit and Seattle, Club 1921 in Charlotte and Phoenix: https://diabetes-connections.com/events/   Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com   Transcript:  (Stacey Track) On this episode of Diabetes Connections In the news… Sanofi acknowledges an insulin shortage, a new oral therapy for type 1 moves along in research, could there be an actual, accurate, non-invasive CGM in the works, ADA conflict continues and I can't wait to tell you about Cookie Queens.. that's coming up right after this. (AD BREAK) Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. We are still looking for your community commercials. These are 30–60 second audio spots created by members of the diabetes community to share: Events you're organizing: a fundraiser, walk, or local meetup Products you've created: maybe you've written a book, have a Substack, designed a T1D-friendly gadget, or launched a small business Helpful projects or resources: things you think others in our community should know about It's your chance to share what you're doing and help others get connected! Full instructions are on the website. While you're there please check out our events. We're turning toward fall and we have a lot going on – MNO and Club 1921.   Okay.. our top story this week: XX I want to talk about Cookie Queens! It might not sound like a hard news story.. but It's my show and I can't wait to watch this. This move follows four Girl Scouts ages 5-12 during cookie season. One of the girls has type 1 – they don't mention it in the trailer, but you can see her omnipod. Here's a clip:   Start the very beginning and stop after "I want to be a supreme court justice." (stop after the "oh..laughter" https://www.youtube.com/watch?v=nnSQS43Eil8   Viewers meet Ara from San Diego, CA (5), Shannon Elizabeth from El Paso, TX (8), Nikki from Chino, CA (9), and Olive from Charlotte, NC (12). Ara has Type 1 diabetes and is shown taking insulin, refilling her pump before bed, and determining with her dad how to sample the cookies she's selling while keeping her blood sugar levels safe. Thumbs down to the Hollywood reporter dot com. In their review they say.. "if this film were itself a baked good, Ara would need to be careful because one bite could cause hyperglycemia or even diabetic ketoacidosis. It's just that sweet." Cookie Queens comes out this month. https://www.hollywoodreporter.com/movies/movie-reviews/cookie-queens-review-prince-harry-meghan-markle-girl-scouts-1236484555/ trailer:   XX Supply issues for Lantus SoloStar pens being acknowledged by Sanofi. The company says it's experiencing "a period of intermittent supply due to increased demand. The company said the increase in demand is being driven by "broader market dynamics," but did not provide additional details. Sanofi said the situation is temporary and is expected to improve over the coming weeks. The company said Lantus U-100 vials and Toujeo U-300, which contain the same active ingredient, remain available. https://www.wral.com/news/local/common-insulin-pen-faces-supply-issues-amid-rising-demand-july-23-2026/ XX The University of Alabama at Birmingham startup TIXiMED Inc. has launched the next phase of clinical testing for a novel oral therapy for Type 1. For now called TIX100, a small-molecule drug designed to inhibit a protein linked to pancreatic beta-cell loss and diabetes progression. The new double-blind, randomized, placebo-controlled study will evaluate the drug's safety, tolerability and pharmacokinetics. Researchers will enroll 18 healthy participants across three dose cohorts at a single United States study site. Participants will receive either TIX100 or a placebo twice daily for 28 days, followed by a seven-day follow-up period. Six participants making up the first cohort have been successfully enrolled thus far. In addition to its potential use in Type 1 diabetes, TIX100 may have applications in Type 2 diabetes and obesity. A recent study found that the drug prevented weight regain and preserved lean muscle mass after discontinuation of GLP-1 therapies in preclinical models. https://www.uab.edu/news/research-innovation/startup-advances-novel-oral-type-1-diabetes-therapy-to-next-phase-of-human-testing XX Researchers at the University of California San Diego say they have developed and validated a Continuous Health Analyzing Ring Module (CHARM), a compact, fully integrated wearable smart ring capable of continuous real-time monitoring of multiple biomarkers in sweat. The wearable device can simultaneously measure up to four biomarkers, including glucose, ketone, uric acid, lactate, ascorbic acid, and alcohol, to provide real-time insights into metabolic health. The study is published in Nature Communications. They say CHARM device contains all necessary biomarker sensors, low-power electronics, and a flexible battery. The left compartment of the device is designed to draw sweat passively using an osmotic hydrogel, a soft polymer that creates a pressure gradient to pull fluid from the skin painlessly. The sweat is then analyzed by multiplexed electrochemical sensor arrays within the same compartment, leading to simultaneous and real-time tracking of four biomarkers at a time.   The right compartment of the device contains a flexible zinc-silver oxide rechargeable battery that supplies power for up to 12 hours of operation between charges. Biomarker information generated through sensors is wirelessly transferred to a connected Bluetooth-enabled device for real-time display The findings indicated that the device performed well in initial temperature, cytotoxicity, and on-body compatibility tests. It also demonstrated high analytical accuracy in preliminary studies involving healthy participants and individuals with type 1 diabetes, highlighting its potential for non-invasive metabolic monitoring. The calculated estimated sweat-based blood glucose concentration showed a mean absolute relative difference of approximately 13.7% against its corresponding blood concentration values.   The device needs further validation in diverse clinical settings and across large diabetic cohorts.   https://www.news-medical.net/news/20260727/Prototype-smart-ring-tracks-multiple-sweat-biomarkers.aspx   XX Hotter weather and rising temps appear to increase the short term risk for low blood sugar in adults with type 1. An analysis of more than 32 million continuous glucose monitor (CGM) readings from nearly 700 adults with T1D in the UK showed a 26% greater risk for hypoglycemia at a temperature of 25 °C (77 °F) than at 13 °C (55.4 °F). Hypoglycemia was defined as a glucose level < 3.9 mmol/L (70 mg/dL). The study included 679 individuals with T1D and 32,966,282 CGM readings collected between February 23, 2017, and August 8, 2024. Participants had a mean age of 46.4 years and a mean T1D duration of 23.7 years. The researchers observed strong seasonal patterns, with lower odds of hypoglycemia in late winter and early spring, followed by a peak during the summer. The lowest risk occurred on Mondays. The odds then increased over the course of the week and peaked toward the weekend, with a significant odds ratio of 1.14 on Saturdays compared with Mondays. Increases in hypoglycemia were observed during both hot and cold weather, but the association was stronger for heat. The net odds ratio was 1.26 at 25 °C compared with 13 °C.   https://www.medscape.com/viewarticle/when-temperatures-climb-hypoglycemia-risk-rises-type-1-2026a1000q4r XX Seven weeks after the expulsion of five diabetes experts from the American Diabetes Association conference, controversy continues. More than 200 members now calling for two ADA leaders to resign. In response, the ADA delivered its own message Tuesday, expressing appreciation for members' patience while a report is prepared.   The resignation demand, sent last week in an open letter to the ADA board of directors, calls for the removal of CEO Charles Henderson and chief scientific and medical officer Rita Kalyani. It also urges "an independent investigation into the events of the 2026 Scientific Sessions in New Orleans, a full apology to the five colleagues removed from the meeting, and the restoration of editorial independence at Diabetes Care," an ADA scientific journal.   https://www.statnews.com/2026/07/28/american-diabetes-association-fallout-researchers-expulsion/ XX XX Still to come, , a new link between diabetes and dementia, device updates, and why you might want to start rooting for the Red Sox..   XX New study says that people diagnosed with type 1 diabetes (T1D) before the age of 10 years had a 37% higher risk of developing all-cause dementia later in life than those diagnosed between ages of 18 and 30 years. These researchers used a Swedish national register of 43,440 individuals with T1D (mean age at cohort entry, 33 years; 44% women) Worth noting a couple of things.. the mean age in this study was 33 – so the people who were diagnosed under the age of ten would not have had access to current technology – no CGMs or AID systems. And while the study says it's 37% higher for the younger group, the actual rate was still very low. As always, I'll link to the study so you can learn more. My obvious bias here to look for a silver lining because I have a son who diagnosed with T1D at age 2.   https://www.medscape.com/viewarticle/type-1-diabetes-onset-before-age-10-tied-higher-risk-2026a1000pir XX Researchers have developed a machine learning model that uses routine clinical information to detect diabetes and distinguish between type 1, type 2, prediabetes, and diabetes caused by pancreatic disease. The model performed well in early testing, but researchers say it still needs to be validated in independent patient groups before it could be considered for use in diabetes screening or clinical care. It did not assess clinical utility, patient outcomes, or quality of life. https://www.news-medical.net/news/20260729/Researchers-train-AI-to-detect-diabetes-and-assign-four-diagnostic-labels.aspx XX Trinity Biotech and Latch Medical are teaming up to explore combining CGM with precision drug delivery technology for diabetes, obesity, and other metabolic conditions. The companies hope real-time glucose data from Trinity's CGM+ sensor could eventually help guide more personalized treatment decisions and medication delivery. Trinity's CGM+ is still in development, with a pivotal clinical trial planned for later this year. https://www.drugdeliverybusiness.com/trinity-biotech-collab-cgm-drug-delivery/ XX The FDA selects Dexcom as the first participant in a new digital health pilot that will exempt certain digital health devices from FDA premarket authorization requirements while collecting real world data through a complementary Medicare program. Dexcom, plans to implement an artificial intelligence-enabled glucose health program through the pilot. The program is intended to help screen for prediabetes and Type 2 diabetes. The company plans to integrate data from its sensors, including its prescription G7 CGM and its over-the-counter Stelo device, along with contextual health information such as nutrition, physical activity, sleep and stress. The FDA announced plans for the Technology-Enabled Meaningful Patient Outcomes, or TEMPO, pilot last year amid a broader push for adoption of digital health and wearables. It coincides with a new program by the CMS to fund the use of digital technologies for managing chronic conditions. https://www.healthcaredive.com/news/fda-names-dexcom-as-first-participant-in-digital-health-pilot/826215/ XX Medicare and Medicare Advantage beneficiaries now have access to the new MiniMed Flex insulin pump. Beneficiaries can now access the MiniMed Flex and its latest sensor portfolio, which currently includes the Simplera Sync sensor, a disposable, all-in-one sensor with easy two-step insertion. The company plans to roll it out with the Instinct sensor, made by Abbott, later this summer. It also added Abbott's dual glucose-ketone sensor (still investigational in the U.S.) to its portfolio this year. Flex picked up FDA clearance in March and the company announced the initial commercial rollout of the pump last month. https://www.drugdeliverybusiness.com/minimed-flex-pump-now-available-medicare/ XX Eli Lilly expands it's partnership with Resilience – the makers of the KwikPen device. Through the investment, Resilience will significantly increase U.S. production of Lilly's KwikPen injectable device for diabetes and obesity medicines. In February, Lilly won FDA approval for Zepbound in a multidose KwikPen device. The product includes four doses of the GLP-1/GIP receptor agonist, providing a month of treatment for obesity or overweight in one device. Resilience expects the KwikPen capacity expansion to create at least 400 jobs in the Cincinnati area. https://www.biospace.com/deals/lilly-and-resilience-invest-750m-in-diabetes-and-obesity-drug-device-supply XX Alex Cooper – the host of the top podcast Call her Daddy – announced she's been diagnosed with gestational diabetes.   "When I got this diagnosis, the first couple days, I was really hard on myself," the 31-year-old admitted. "It felt very isolating, like, as much as my family and my husband and everyone was there for me I just felt like, it's me on an island." She says she found an online community that's been helping. In sharing her experience, she hoped it would alleviate the stress. https://www.eonline.com/news/1434556/pregnant-alex-cooper-shares-isolating-gestational-diabetes-diagnosis XX Several amazing diabetes non profits are vying for big charity dollars from the Boston Red Sox. The IMPACT Awards provide Red Sox fans with the chance to nominate their favorite, most impactful nonprofit organization serving New England for their opportunity to win a grant from the Red Sox Foundation. In 2026, the IMPACT Awards will focus on organizations that are supporting research and providing awareness, advocacy, and services to people with diabetes. Check out all the charities and vote for your favorites – you've heard of so many of these I promise – at the link in the episode show notes, . https://www.mlb.com/redsox/community/red-sox-foundation/impact-awards?partnerId=redirect-bos-impact

Novo Nordisk has spent years warning patients, regulators, lawmakers, and courts about the risks of synthetic semaglutide. Now, as patents begin to expire and China's pharmaceutical industry becomes increasingly important, Novo may be staring at a very uncomfortable question: what happens if synthetic semaglutide suddenly makes sense when Novo is the one making it?In this week's episode of The Weekly Dose, I dig into Novo's long-running recombinant-versus-synthetic semaglutide argument, the lawsuits and FDA petitions built around it, and a clip from more than 16 months ago showing that we were covering this exact issue long before it became part of the mainstream conversation. Novo Warned Us About Synthetic Semaglutide_ Now This_.txtWe also break down Pfizer's decision to kill two clinical-stage obesity drugs, including an oral GLP-1 acquired through its $10 billion Metsera deal, the strange science behind GIP receptor antagonism, and why Pfizer's remaining obesity pipeline still deserves attention. Plus, Wall Street is looking at Eli Lilly's obesity-fueled rally and asking just how big this market can get.In this episode:00:00 Novo's synthetic semaglutide problem02:00 VoaFit sponsor message03:30 The 16-month-old On The Pen receipt05:00 Recombinant vs. synthetic semaglutide07:00 Novo's FDA, legal, and political strategy09:00 Pfizer kills two obesity drugs11:00 What happened to Metsera's oral pipeline?13:00 The GIP agonist vs. antagonist paradox15:00 Why China matters to Pfizer and Novo17:00 Could Novo eventually make synthetic semaglutide?18:30 What comes next for Lilly, Novo, and PfizerThe big question: If Novo Nordisk eventually launches its own synthetically manufactured semaglutide, does that change how you view the arguments it has made against compounded semaglutide over the last several years?Comment below. I want to know where you land.More obesity medicine news and analysis: OnThePen.comAll my links, socials, and resources: linktr.ee/manonthemounjaroThis episode is sponsored by VoaFit. Learn more at voafit.com/otp.#GLP1 #Semaglutide #Ozempic #Wegovy #NovoNordisk #CompoundedSemaglutide #ObesityMedicine #Pfizer #EliLilly #Mounjaro #Zepbound #Metsera

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!Triple hormone receptor agonism is emerging as a frontier in metabolic disease treatment, and topline phase 3 results for retatrutide suggest the strategy can push weight loss and glycemic control beyond current incretin therapies, even as a separate JAMA analysis raises questions about oversight in online GLP-1 prescribing.1,2On the latest episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, reviewed topline results from the TRIUMPH-2 and TRIUMPH-3 trials of retatrutide, a glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptor triple agonist.TRIUMPH-2 enrolled 1000 participants with type 2 diabetes across 98 centers and tested 4 mg, 9 mg, and 12 mg doses against placebo over 80 weeks. The 12 mg dose produced weight loss up to 21% from a baseline of 106 kg, or roughly 23 kg. Hemoglobin A1C fell between 1.4 and 1.6 percentage points from a baseline of 7.7%, versus 0.2 points with placebo, a large glycemic effect given the near-normal starting A1C and discontinuation of 14% at the highest dose.TRIUMPH-3 enrolled over 1900 participants with class II or III obesity (body mass index of 35 or higher) and established cardiovascular disease, randomized to 9 mg, 12 mg, or placebo over 80 weeks. The 12 mg dose delivered 23% weight loss versus 3% with placebo, alongside a 37% reduction in triglycerides, 17% reduction in non-high-density lipoprotein cholesterol, and 9.3 mmHg reduction in systolic blood pressure. Major adverse cardiovascular event outcomes trended favorably but did not reach significance, an expected limitation of an 80-week trial.Gastrointestinal effects were common across both trials, including diarrhea in up to 34% of participants and nausea in up to 28%, consistent with the broader incretin class.Isaacs and Bellini also discussed a JAMA secret-shopper study, led by Ashwin Chetty, MD, examining online GLP-1 prescribing across 49 telehealth websites. Of these, 92% prescribed the requested medication and 70% mailed it, often without required photo verification, blood work, or clinician video visits, in some cases within five minutes. Compounded formulations, including unproven sublingual drops, were frequently offered alongside add-on supplements marketed as personalization, a workaround linked to compounding rules requiring documented medical need.Together, the findings illustrate a widening gap between the therapeutic ceiling GLP-1-based agents are reaching in controlled trials and the variable oversight surrounding real-world access to these drugs, underscoring the need for clinicians to proactively screen patients for unsupervised use.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

Digestion is regulated by a complex network of hormones, peptides, and neural signals. In this episode, we review the major gastrointestinal hormones, introduce several secondary regulatory peptides, and explain how the GI tract senses its luminal contents and integrates multiple signals to control digestive function. After listening to this episode, you should be able to: Identify the source, release stimulus, and function of the major gastrointestinal hormones, including secretin, cholecystokinin (CCK), gastrin, and vasoactive intestinal peptide (VIP). Summarize the release stimuli and functions of key GI regulatory peptides, including bombesin, GLP-1, GLP-2, ghrelin, leptin, motilin, somatostatin, and glucose-dependent insulinotropic polypeptide (GIP). Explain how the physical and chemical properties of luminal contents are sensed and how they trigger hormonal responses. Describe how GI cells integrate hormonal and neural inputs to regulate digestive function. You can also check out the original brick on Gastrointestinal Regulatory Substances from our Gastrointestinal collection, which is available for free. Explore more with USMLE-Rx Create a free USMLE-Rx account at www.usmle-rx.com. You'll receive five days of full access to Rx360+, including over 800 Rx Bricks. After the trial, you can continue accessing more than 150 free Bricks, including the complete General Microbiology and Cellular and Molecular Biology collections. Enjoyed the episode? Please consider leaving us a review on Apple Podcasts. Reviews help more medical students and future medical students discover the podcast…and help us continue creating resources for the physicians of tomorrow.

As current understandings of obesity (ie, a chronic disease requiring long-term management) are adopted across the world, screening and treatment can no longer follow a one-size-fits-all approach. Listen in as 3 global experts in obesity medicine highlight the emerging evidence from recent conferences that are changing real-world practice today. Learn how the latest findings apply to specific patient populations across the United States, Europe, and Asia as well as why healthcare professionals should individualize treatment based on patient preferences and relevant risk factors. Presenters: Stephano Del Prato, MD Professor Emeritus of Endocrinology University of Pisa Pisa, Italy Soo Lim, MD, PhD Professor of Medicine Department of Internal Medicine Seoul National University College of Medicine and Seoul National University Bundang Hospital Seoul, South Korea Donna H. Ryan, MD Professor Emerita Pennington Biomedical Research Center Louisiana State University New Orleans, Louisiana Link to full program:https://bit.ly/4pwFhEo Get access to all of our new podcasts by subscribing to the Decera Clinical Education Multispecialty Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Chalene Johnson breaks down retatrutide, the peptide everyone is calling a GLP-3 and an Ozempic killer, cutting through the hype to get to what the science actually says. Eli Lilly's own clinical trials show weight loss results that beat anything semaglutide or tirzepatide has produced, but retatrutide is not FDA approved and is not legally available at any US pharmacy, which means almost nobody buying it online is actually getting the real thing. Chalene explains what retatrutide actually is (a triple agonist that adds glucagon receptor activity to the GLP-1 and GIP receptors already targeted by Ozempic, Wegovy, Mounjaro, and Zepbound), walks through what the phase three trial data really shows versus how it is being exaggerated online, and shares why an independent lab test of vials sold through TikTok, med spas, and Reddit found most contained only 7 to 14 percent of anything resembling the real molecule. She also unpacks the muscle preservation claims that are not backed by human data, the anhedonia and placebo effect reports circulating online, why bariatric surgery comparisons need context, and how to find a reputable source like Midi Health for anyone considering a GLP-1 through legitimate medical channels. Topics discussed: retatrutide, Ozempic, semaglutide, Wegovy, tirzepatide, Mounjaro, Zepbound, GLP-1, GLP-3, Eli Lilly, bariatric surgery, Midi Health, anhedonia, muscle wasting, peptides, BPC 157 Go Beyond The Podcast Join Chalene on her private podcast

In deze extra lange special aflevering zijn we opzoek bij de Boeren van Amstel. Dit is een groep van 18 boeren die houden van hun vak, liefde voor de natuur en toegewijd aan het behoud van groen zo dicht bij de stad. Met het oog op een duurzame toekomst voor het mooie Amstelland zijn de boeren opzoek gegaan naar een alternatief verdienmodel. Daarbij doen ze aan agrarisch natuurbeheer met kruidenrijke graslanden. Dit is een ideaal gebied waar weidevogels kunnen broeden. Dat is een verhaal dat we graag met jullie delen en dus gaan we in gesprek met de verschillende betrokkenen. Maar er wordt natuurlijk ook gevogeld en geloof het of niet, maar Gip ontdekt tijdens deze podcast zijn most wanted vogel en misschien wel de belangrijkste vogel van zijn Big Year. Zie het privacybeleid op https://art19.com/privacy en de privacyverklaring van Californië op https://art19.com/privacy#do-not-sell-my-info.

Stephen Grootes speaks to Ruaan Louw, Managing Director of iDexis, about the company's decision to appeal a recent High Court judgment and regulatory findings relating to its compounding of GLP-1 and GIP medicines. iDexis maintains that its products were safe, says independent testing found no evidence of sterility failures, and argues that regulators were aware of its compounding activities long before the dispute reached court. The Money Show is a podcast hosted by well-known journalist and radio presenter, Stephen Grootes. He explores the latest economic trends, business developments, investment opportunities, and personal finance strategies. Each episode features engaging conversations with top newsmakers, industry experts, financial advisors, entrepreneurs, and politicians, offering you thought-provoking insights to navigate the ever-changing financial landscape.    Thank you for listening to a podcast from The Money Show Listen live Primedia+ weekdays from 18:00 and 20:00 (SA Time) to The Money Show with Stephen Grootes broadcast on 702 https://buff.ly/gk3y0Kj and CapeTalk https://buff.ly/NnFM3Nk For more from the show, go to https://buff.ly/7QpH0jY or find all the catch-up podcasts here https://buff.ly/PlhvUVe Subscribe to The Money Show Daily Newsletter and the Weekly Business Wrap here https://buff.ly/v5mfetc The Money Show is brought to you by Absa     Follow us on social media   702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/CapeTalk 702 on YouTube: https://www.youtube.com/@radio702   CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/Radio702 CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Cheaper obesity medicines could unlock broader demand, while supply-chain bottlenecks and premium-drug innovation may also shape how the market evolves. Our analysts Terence Flynn and Thibault Boutherin break down the investor implications.Read more insights from Morgan Stanley.----- Transcript -----Terence Flynn: Welcome to Thoughts on the Market. I'm Terence Flynn, Morgan Stanley's U.S. Pharma and Biotech Analyst. Thibault Boutherin: And I'm Thibault Boutherin, Morgan Stanley's Europe Pharmaceuticals Analyst. Terence Flynn: Today, how cheaper GLP-1 obesity medicines could reshape access, pricing, and supply chains; and what the first generic markets may signal for Europe and the U.S. It's Monday, July 13th at 10am in New York. Thibault Boutherin: And it's 3 pm in London. Terence Flynn: Around one billion people live with obesity worldwide, including over a 100 million in the U.S. Right now, the introduction of the first lower cost generics of semaglutide, a GLP-1 medicine, in some international markets, could have consequences on affordability and demand. Thibault, what are the first countries seeing the introduction of sema generics? What are the current dynamics, and why should global investors pay attention? Thibault Boutherin: Sure. So, so far generics are being introduced this year in three countries: in India, Canada and Brazil. And if we look at India, this is the first market where the generics are being introduced. The patent for semaglutide expired in March 2026, and 13 companies have launched 26 generics across different formulations: autoinjectors, vials, and pills, which price is lower than the branded drug. And because the India market was quite under-penetrated for GLP-1, we are seeing affordability driving volume expansion. In Canada, two generics have been launched so far. Four other generics are waiting for approval, and more are being filed. And finally, in Brazil, one generic was approved last month, and we are expecting these generics to be launched in Brazil in July. And 17 other generics are in different stage of regulatory review in Brazil, and we would expect more to enter the market by the end of this year. And the reason why we focus on these markets is because we believe they could provide a blueprint for what could happen later in the U.S. and in Europe; in particular for Canada, which shares some characteristics with Europe and the U.S. And the patent for semaglutide will expire in Europe in 2031 and in the U.S. from 2032. Terence Flynn: Great. Maybe on the India front, I know that's at the leading edge. What happened with patient demand when price came down? Thibault Boutherin: Sure. So, what we saw in India is a surge in volume when generics were launched, and the volume in April 2026 were already six times higher than the volume in February. And that expansion has been driven mostly by these generics launch, which captured 80 percent of semaglutide volume in April. And our India team expect that the GLP-1 market in India will actually expand in value from $125 million in [20]25 to more than $1 billion by 2030, despite lower prices as we see better, you know, greater volume and greater adoption of GLP-1s in India. Terence Flynn: The other thing, you know, you and I have discussed is the supply chain, and one of the questions is the ability of some of the generic manufacturers to scale semaglutide. So, maybe talk to us about the current capabilities. And could we see bottlenecks in the supply chain formation here? Thibault Boutherin: Yeah, sure. So, there are three key elements to watch on the supply chain. The first is the active pharmaceutical ingredient or API, and that's the semaglutide molecule itself. The second element is the device and the device components, and the third element is the fill and finish, which is basically putting all of these things together. On the API side, so semaglutide molecule, we believe there will be no bottleneck in supplying for generics as we see a handful of large Chinese companies, out of China, building multi-ton capacity for semaglutide. So, we believe there will be no shortage of API to supply the generic supply chain for injectables. On the device, these are the same device companies that are supplying the branded version of semaglutide, and other GLP-1s for the device that are also supplying the generic makers. And we are seeing meaningful investments being made, so we don't believe there will be a bottleneck here. Where we could see a bottleneck emerging is on the fill and finish side. Fill and finish requires highly controlled clean room space to minimize contamination. It requires regulatory approval, and it takes up to three years to build fill and finish capacity. And so, that's where if there is not more investment being made over the next few years, there could potentially [be] a bottleneck emerging for the generic companies. Terence, while semaglutide generics will definitely represent a challenge for the existing branded version of this GLP-1, there are some insights in these emerging dynamics that suggest that tirzepatide, the other GLP-1, could be less at risk. Can you touch a bit on some of these dynamics? Terence Flynn: Absolutely. So, just to remind listeners that semaglutide targets a pathway called GLP-1. Tirzepatide actually targets two pathways. The first is GLP-1, and the second is GIP. And there are some data comparing these molecules, both in Type 2 diabetes and obesity. And tirzepatide gives not only better efficacy but also improved tolerability. And so, what you're seeing in some of the ex-U.S. markets is segmentation, where there are some consumers that are willing to pay a premium price for tirzepatide. Our team in Brazil has done a lot of work on this front looking at this dynamic and, you know, we expect that to play out in many geographies. So, despite the entry of lower-cost generic versions, we think you will still see segmentation of the market between differentiated brand and the lower-cost generics. And that as a result, you will continue to see branded growth.In the U.S. right now, market share is about 60 percent in favor of tirzepatide. And so again, you're seeing a differentiation between these two molecules. Thibault Boutherin: And beyond the introduction of generics GLP-1s, there are other dynamics in the industry that are driving this market. And the introduction of oral drugs this year has been a big topic. Terence, what are your views on the role that orals could play on the market? Terence Flynn: Yes, as a lot of people are probably aware, the many of the existing GLP-1 medicines are injectable. And so those are delivered once a week with a needle. But there are now additional oral options of these GLP-1 medicines. They started off first for Type 2 diabetes, but they have now broadened into obesity as well, following some recent FDA approvals. And what we're seeing is that the introduction in the U.S. so far is expanding the market. So, the majority of people that are taking the oral versions of these medicines are new users to GLP-1s. So again, you're getting market expansion. When you think about the orals as well, one of the other questions is capacity. I know, Thibault, you were talking about the supply chain. There are similar questions for these oral medicines because not all of the oral medicines are the same. Some are easier to manufacture than others, and as a result, that's another variable to consider. So, some of these are what's called peptide-based orals, and some of these are non-peptide-based orals. And the non-peptide-based orals are much easier to scale, for a larger global market. And so that's definitely another variable that we're monitoring and that I think investors need to consider. Thibault Boutherin: And beyond the pill versions of these GLP-1s, we are seeing more innovation in the drug pipeline of the industry, which could be a key driver of differentiation against the competition from the generics. So, what are we seeing emerging today from diabetes and obesity pipelines, which could be exciting for the future of the category? Terence Flynn: So, as we see time and time again in pharmaceutical markets, the key players continue to innovate to try to improve profiles of the existing medications. So, there are, you know, kind of two areas. One would be efficacy; another would be safety tolerability. And so, there are a number of players that are working first to develop longer acting medication. So, as I mentioned, the existing injectable drugs are dosed once weekly. But there are a number of companies that are working to develop potentially monthly or less frequent injections. So, that's one area that we're monitoring closely. And then the second, and again, this plays into what I discussed on tirzepatide, is additional pathways that are involved here in diabetes and obesity, and a number of players are working to target additional pathways beyond GLP-1 and GIP. And so, some of the leading pathways that are being studied are something called amylin and glucagon, and there are a number of medications that are in the late-stage pipeline that are coming along, which have some pretty interesting data. And so that's another area that we're watching. And again, the goal there would be to either improve efficacy and/or improve tolerability versus the existing medications. Thibault Boutherin: Great. And maybe we can also take this opportunity to talk about some of the short-term drivers in the market that are not facing generic today, like the U.S. So, what could be, you know, the key drivers for growth of GLP-1s and the overall obesity and diabetes category over the next five years? Terence Flynn: Yeah, obviously the key one is seeing additional uptake of these medicines. I think right now we estimate, again, obesity in particular, there's about low double-digit percent uptake. And so obviously seeing increasing uptake of these medicines. The orals, as I mentioned, are already driving market expansion. And then the third is access. So obviously in any market, that's very important. In the U.S., I think about 50 percent of employers cover these medications right now. We expect that to increase in the years ahead as the data continues to build. But then this year starting very shortly, the patients in the Medicare program in the U.S., so those people over the age of 65, will be able to access these medicines for $50 per month. And so, we think that is another driver of growth – is this will broaden access to about an additional 18 million people, starting this summer. So, the next phase of the diabesity market comes down to execution, lower cost and scaled supply in the mass market, and innovation and differentiation to compete in the premium segment. Thibault, thanks so much for taking the time to talk. Thibault Boutherin: Great speaking with you, Terence. Terence Flynn: And thanks for listening. If you enjoy Thoughts on the Market, please leave us a review wherever you listen and share the podcast with a friend or colleague today.

Send us Fan MailPeptides are suddenly the hottest word in weight loss clinics, gyms, and wellness circles, but most people are hearing the hype without the definitions, the evidence, or the safety guardrails. Speaking of Women's Health Podcast host Holly Thacker, MD sits down with Layth Tumah, MD, a Cleveland Clinic physician board certified in family medicine, obesity medicine, lifestyle medicine, and trained in functional medicine, to explain what peptides actually are: short chains of amino acids that act as powerful signals in the body, sometimes in ways that look a lot like hormones.They get practical about the peptides people are most likely to encounter through their doctor: GLP-1 and GIP based medications used for diabetes and medical weight management. They clarify how the same underlying drug can be sold under different brand names depending on the indication, why shortages fueled interest in compounding pharmacies, and when compounding is a reasonable tool versus a risky shortcut. They also talk about the deeper “why” behind today's metabolic disease surge and why these therapies can matter for health span, not just the number on the scale.They end where real prevention always starts: food, movement, sleep, stress coping, and connection, plus the reminder that there is no "free lunch" when it comes to powerful supplements. Support the show

In this special live episode recorded from the SLEEP 2026 annual meeting in Baltimore, host Dr. Seema Khosla welcomes Dr. Sanjay Patel, director of the clinical sleep program at University of Pittsburgh Medical Center, to discuss groundbreaking medications for sleep disorders poised for FDA approval in 2026 and 2027. The pharmaceutical landscape for sleep medicine is undergoing unprecedented transformation. Dr. Patel surveys the emerging drug pipeline that will fundamentally change how clinicians treat obstructive sleep apnea, narcolepsy, and idiopathic hypersomnia. For obstructive sleep apnea, Dr. Patel discusses AD-109 (atomoxetine and R-oxybutynin), explaining the mechanistic rationale and practical considerations including use with tirzepatide. The Incannex drug combining dronabinol and acetazolamide receives analysis for different patient populations, and sultiame is discussed as a carbonic anhydrase inhibitor option. A critical framework emerges: Should treatment be symptom-based or airway-focused when PAP-intolerant patients present? Tirzepatide, the GLP-1 agonist FDA-approved for moderate-to-severe OSA, receives comprehensive coverage including muscle loss concerns, long-term use, and emerging oral GLP-1 options. Retatrutide, the triple-hormone agent combining GLP-1, GIP, and glucagon, is also discussed. The episode's most exciting segment focuses on orexin agonists for narcolepsy. Three pharmaceutical companies—Alkemeres, Centessa (purchased by Lilly), and Takeda—are developing these mechanistically novel agents. Dr. Patel clarifies how these medications differ, discusses why one medication disrupted nocturnal sleep (suggesting continued roles for oxybates), and addresses how clinicians will choose between similar medications. Dr. Patel emphasizes a fundamental question: Should the field prioritize symptom management versus airway patency for OSA, and mechanistic approaches versus symptom management for narcolepsy? Whether you're interested in emerging OSA treatments, narcolepsy innovations, or the future of pharmacological sleep medicine, this live episode provides essential updates on medications that will soon reshape clinical practice. Join us for this exciting conversation about how sleep medicine will transform in the coming years.

GLP-1 receptor agonists have become some of the most talked-about medications in recent years. You may have heard names such as liraglutide, semaglutide (Ozempic and Wegovy), and tirzepatide (Mounjaro). These treatments have attracted attention because they can significantly reduce appetite and support weight loss while also helping to manage blood glucose levels. The breakthrough came when researchers developed long-acting versions of hormones naturally released by the body after eating, including GLP-1 and, in some cases, GIP. These hormones help regulate hunger and promote feelings of fullness. While the body's natural response lasts only a short time, modern medications extend these effects for up to a week with a single injection. Since results from major clinical trials emerged in the early 2020s, GLP-1 therapies have transformed obesity treatment, delivering weight-loss outcomes that surpass those achieved by previous medications and offering new hope for people struggling with weight management. - Laureate Professor Clare Collins, internationally distinguished leader in nutrition and dietetics, University of NewcastleSee omnystudio.com/listener for privacy information.

Send us Fan MailFreedom is not just a political idea, it's also the ability to move through your day with energy, confidence, and choices that are not dictated by symptoms or chronic disease. We connect America's 250th anniversary theme of “life, liberty, and the pursuit of happiness” to a very current women's health reality: the obesity epidemic and the frustration many midlife women feel when weight changes collide with hot flashes, sleep loss, and brain fog.We break down common myths around menopause and weight, including the claim that menopausal hormone therapy causes obesity, and we explain what the research actually shows. Then we step into the fast-changing world of weight loss medications, from older drugs that were removed from the market to today's GLP-1 and GIP agents. Then we zoom out to something many people underestimate: social connection as a true health intervention. Social Wellness Month is a reminder that loneliness can harm health in ways that resemble other major risk factors. We share practical ways to build deeper relationships, volunteer, use technology wisely, and create summer traditions that strengthen community. You'll also get healthier July 4th menu ideas, simple recipe inspiration, and summer safety reminders from hydration to fireworks.Follow the show so you do not miss what's next, share this with a friend who needs a reset, and leave a review to help more women find evidence-based health guidance.Support the show

Send us Fan MailOBGYN Dr. Richard Myers joins Dr. Erich Schramm to discuss the name change from Polycystic Ovarian Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS). This syndrome is the combination of three parts: increased polyendocrine hormones (like insulin and androgens), changing metabolism, and differences in ovarian function Dr. Myers explains that the name change to PMOS reflects the changing understanding and focus of the syndrome from a purely ovarian-centered approach to a more holistic, full-body treatment regimen. The doctors also discuss how different patient desires drive different treatment options and the need for individualized, patient-centered care. They finish by looking at new treatments, including GLP-1 and GIP medications that can help address the underlying metabolic components of the PMOS.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Welcome to the latest episode (July 2026) of DOC Updates, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease. This month on DOC Updates: Aroda V, Buzzetti R, Dalskov S et al. "Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study." The Lancet Diabetes & Endocrinology, 2026; 0 doi: 10.1016/S2213-8587(26)00126-9 Bajaj H, Welch M, Shah P et al. "Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial." The Lancet, 2026; 407, 2402-2413 doi: 10.1016/S0140-6736(26)00967-0 Melville, N. "CGM Monitoring Benefits Extend to Non-Insulin-Using T2D." Medscape, June 07, 2026 Aronne, L.J., Horn, D.B., le Roux, C.W. et al. "Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial." Nat Med(2026) doi: 10.1038/s41591-026-04386-7 Salive ME, Tjaden AH, Ames JR, et al. "Lifestyle and Metformin Interventions and Risk of Multimorbidity in Adults With Prediabetes." JAMA. Published online June 15, 2026. doi:10.1001/jama.2026.8492 Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health For information about the American Diabetes Association's scholarly journals, visit diabetesjournals.org. For more about this podcast, visit About Diabetes Core Update.

Sarah Kennedy of Calocurb explains why food noise spikes in perimenopause: falling estrogen raises cravings while the hindbrain overrides forebrain willpower under stress or poor sleep. She contrasts natural appetite hormones (GLP-1, GIP, CCK, PYY) with pharmaceutical GLP-1 agonists, which run at roughly 3,000% physiological levels versus the body's natural 300% rise - explaining rebound hunger after stopping injectables. Calocurb, a hops-derived bitter compound, stimulates a 600% natural hormone rise for an 18% average calorie reduction. WHAT YOU'LL LEARN Why food noise isn't a willpower problem, and what's actually happening in your hindbrain versus your forebrain when cravings take over How declining estrogen in perimenopause changes your calorie needs even as cravings increase What GLP-1, GIP, CCK, and PYY actually do in your body, and how they differ from each other How pharmaceutical GLP-1 agonists compare to your body's own natural hormone levels, and what that gap means for nutrient intake Why coming off a GLP-1 medication can trigger intense rebound hunger, and what's happening hormonally during that transition How bitter taste receptors throughout your gut influence appetite signaling, and why this evolutionary mechanism matters What role the luteal phase, travel, and sleep deprivation play in cravings, and how timing strategies can offset them TIMESTAMPS 00:00 - Intro  00:58 - Willpower vs. Biology: The Hindbrain-Forebrain Battle Driving Cravings  04:58 - GLP-1 Explained: How Natural Appetite Hormones Actually Work 10:21 – Supraphysiological Dosing on GLP-1 Drugs and Nutrient Sufficiency Risks  14:03 – Bitter Taste Receptors: The Gut-Brain Mechanism Behind Appetite Suppression  16:58 – Managing Mindless Snacking, Grazing, and the "Licks, Sips, and Dips" Problem  22:06 – Using Appetite Support Strategically During Weight Loss Plateaus  26:26 – Onboarding, Dosing, and Managing Digestive Side Effects  28:13 – Blood Sugar Regulation and New Clinical Research on Weight Loss Outcomes  30:51 – Why You Must Transition Off GLP-1s Strategically to Avoid Rebound Weight Gain  36:53 – Mood, Motivation, and the Liberating Effect of Quieting Food Noise  39:44 – Closing Thoughts VALUABLE RESOURCES• Take the BioSyncing Quiz to help you understand what's actually happening in your body — and how to fix it.

In this podcast, Jennifer Green, MD, and Jay H. Shubrook, DO, FAAFP, FACOFP, share strategies for integrating incretin-based therapies in type 2 diabetes (T2D) management in the primary care setting, including: Importance of moving beyond a glucose-centric approach to T2D care  Current evidence for incretin-based therapies in T2D Rationale for integrating these therapies into the primary care setting Shared decision-making strategies to discuss optimal T2D treatment options with patients Timing for endocrinology referral Presenters: Jennifer Green, MD Professor of Medicine Division of Endocrinology Duke Clinical Research Institute Duke University School of Medicine Durham, North Carolina Jay H. Shubrook, DO, FAAFP, FACOFP Professor, Diabetologist Department of Clinical Sciences and Community Medicine Touro University California, College of Osteopathic Medicine Vallejo, California Full program link: https://bit.ly/4uSKCqv Get access to all of our new podcasts by subscribing to the Decera Clinical Education Multispecialty Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Nee, maak je geen zorgen Arjan blijft nog voorlopig nog gewoon als number one gids en mentor van de Vogelspotcast. Maar we hebben dit keer wel een speciale aflevering. We gaan namelijk op pad met Waldemar. Waldemar is 13 jaar en een van de jongste fans van de Vogelspotcast. Als klein jongetje ging hij al mee op excursies met ons en nu zit die al op de middelbare school. Wat gaat de tijd toch hard. Maar Waldemar is niet zomaar een hobby vogelaar. Hij vertoont dezelfde trekjes die Arjan op zijn leeftijd had; het liefst voor en na school vogelen, elk moment van de dag met vogels bezig zijn, al zijn vakanties staan in het teken van nieuwe soorten en hij werkt al langzaam aan zijn zelf ontdek lijst. Kortom, de nieuwe Arjan in de dop. Ook volgt hij Gip's Big Year op de voet en hij zag dat hij nog een paar soorten miste die hij veel ziet op zijn local patch. Dus heeft die ons benaderd om een aflevering op te nemen. Nou dat konden we niet afslaan. En sterker nog het was zo succesvol dat h et een dubbele aflevering is geworden. Gip heeft iig weer wat soorten op zijn lijst en daar gaat het per slot van rekening om dit seizoen.Partnerships: Sprinklr is dé pionier in het aanbieden van biologische tuinplanten en werkt met maar liefst 17 biologische kwekers samen om het grootste aanbod gifvrij geteelde planten aan te bieden. Met de kortingscode VogelspotcastBio krijg je 5 Euro korting. Ga naar LINK en bekijk het prachtige aanbod. Zie het privacybeleid op https://art19.com/privacy en de privacyverklaring van Californië op https://art19.com/privacy#do-not-sell-my-info.

Send a Text Message. Please include your name and email so we can answer you! Please note, this does not subscribe you to our email list, it's just to answer if you have a questions for us. A weight-loss injection with results on par with bariatric surgery? With retatrutide, that is not an exaggeration.Although it's not FDA approved yet, retatrutide is one of the most talked-about medications coming down the line. In this episode, I'm unpacking Eli Lilly's new “triple agonist” medication, which targets three different pathways: GLP-1, GIP, and glucagon.We'll talk about how retatrutide may help curb appetite, support insulin sensitivity, increase energy expenditure, and accelerate fat metabolism.I'll also walk you through the standout clinical trial numbers behind the hype and take an honest look at tolerability, discontinuation rates, and side effects, including nausea, diarrhoea, and vomiting, so you can understand the full picture.ReferencesHarvard Study: Benefits of Micro Walks Cali Boyz BurritosSecure your spot for the September round of The 30/30 Program now (spaces limited).Subscribe to my Youtube channelAll of the information on this podcast is for general informational purposes only. Please talk to your physician and medical team about what is right for you. No medical advice is being on this podcast. If you live in Indiana or Illinois and want to work with doctor Matthea Rentea, you can find out more on www.RenteaClinic.com Not Sure Where to Start With the Podcast? I've Got You.Get my free Podcast Roadmap—a simple guide to help you find the episodes that matter most to your journey. Whether you're on GLP-1s, navigating plateaus, or just starting out, there's something here for you.Support the show

Doctor Mau Informa ®️ #drmauinforma Durante medio siglo, la endocrinología consideró al glucagón como el "villano" del metabolismo: la hormona responsable de subir el azúcar en la sangre. Sin embargo, ¿qué pasaría si pudiéramos domesticar a este villano para activar la quema extrema de grasa de forma segura. En este episodio de Doctor Mau Informa, analizamos la fascinante evolución científica que nos llevó desde tumores pancreáticos hasta el desarrollo del Retatrutide, un revolucionario fármaco "triple agonista". Descubre cómo la ciencia logró combinar tres señales hormonales (Glucagón, GLP-1 y GIP) en una sola inyección semanal para alcanzar resultados de pérdida de peso metabólica que antes solo le pertenecían al bisturí de la cirugía bariátrica. En este episodio aprenderás: → La balanza de la pérdida de peso: Por qué los medicamentos anteriores solo te quitaban el hambre, y cómo la nueva generación también acelera tu gasto energético. → El secreto del Glucagón: Cómo esta hormona del ayuno saca la grasa del hígado y eleva el metabolismo. → La evolución del GLP-1: El papel protector de la insulina natural para contrarrestar el azúcar y permitir una pérdida de peso segura. → Cirugía vs. Fármacos: Por qué los resultados de los nuevos tratamientos crónicos están cambiando el paradigma médico para siempre. → La realidad clínica: Efectos secundarios, la importancia de la titulación médica y por qué esto no es una "dieta milagro".

Lieve luisteraars. Door een fabrieksfout van onze geluidsapparatuur is de derde en laatste aflevering van het Lauwersmeer helaas mislukt. Als troost doen we wel een recap van de aflevering zodat jullie er toch een beetje bij waren. Deze aflevering zijn we in de Groene Jonker, maar ook daar vertoonde onze nieuwe apparatuur weer kuren, waardoor Gisbert's geluidsspoor continu oversloeg zonder dat we dat doorhadden. Het is dus allemaal beetje behelpen zoals u merkt... Maar Arjan heeft er flink aan zitten klussen en daarmee is het ergste verholpen. Maar het is verre van perfect. Toch hebben we besloten om de aflevering live te zetten, want 'the show must go on'. Er wordt namelijk wel veel gelachen en er zijn drie nieuwe soorten voor Gip's Big Year gescored. Hopelijk vergeven jullie het ons en we beloven dat er achter de schermen wordt hard gewerkt aan de audiokwaliteit. Dank voor jullie begrip en hopelijk kunnen jullie toch genieten van deze aflevering. Zie het privacybeleid op https://art19.com/privacy en de privacyverklaring van Californië op https://art19.com/privacy#do-not-sell-my-info.

It's In The News - a look at the top diabetes stories and headlines happening now!   Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcript: fall Detroit and Seattle.   Okay.. our top story this week: XX The FDA approved Tzield for use in stage 3 T1D – that's what we used to just call type 1. It's the stage where the body can no longer produce enough insulin on its own to manage blood sugars you need to start insulin. This approval is for kids ages 8-17 within 8 weeks of a stage 3 T1D diagnosis. It comes after the PROTECT trial and it's the first approval of a disease-modifying therapy for stage 3 T1D. https://www.prnewswire.com/news-releases/breakthrough-t1d-celebrates-approval-of-tzield-for-use-in-stage-3-type-1-diabetes-in-the-us-302799532.html XX Encouraging results from a small study of islet cell transplantation in people with type 1 where now all 12 participants in the trial are currently living without external insulin after receiving transplanted insulin-producing islet cells.   The study, led by researchers at the University of Chicago, tested an experimental immune therapy called tegoprubart Te-GO-Proo-Bart. The drug is designed to prevent the body from rejecting transplanted cells while avoiding some of the side effects associated with standard anti-rejection medications. You've probably heard about this as the Eledon study – many of the participants have been very active on social media. It was presented at ADA. transplants.https://www.breakthrought1d.org/news-and-updates/tegoprubart-islet-transplant-all-participants-off-external-insulin/ XX New data suggest that acmopatide (ack-MOW-puh-tyd) (CT-868), an experimental once-daily dual GLP-1/GIP receptor agonist, may help people with type 1 diabetes improve blood sugar control, lose weight, and reduce insulin use. Across all doses, participants lost up to 7% of their body weight and reduced insulin use by as much as 15%. The study lasted just 16 weeks, so researchers say longer-term data will be needed to determine whether the benefits can be maintained and whether lower insulin requirements can be achieved without increasing the risk of hypoglycemia. XX A new combination therapy that pairs an amylin analog with semaglutide improved both blood sugar levels and weight loss in several groups of people with type 2 diabetes. The once-weekly injectable, known as CagriSema (KAG-ruh-SEM-uh), was evaluated in three Phase 3 REIMAGINE studies. In people early in the course of type 2 diabetes, researchers reported A1C reductions of up to 1.8 percentage points and significant weight loss compared to placebo after 40 weeks of treatment. Investigators also noted improvements in several cardiometabolic risk factors, including blood pressure. https://www.medpagetoday.com/meetingcoverage/ada/121658 XX Stelo for kids is now FDA cleared.. the over the counter Glucose Biosensor System is now approved for children as young as 2 years old who do not use insulin. The FDA identified pediatric prediabetes as a growing public health concern motivating the expanded indication, noting OTC CGMs can help younger users and their caregivers build glycemic awareness, track patterns in response to me https://www.hcplive.com/view/fda-clears-first-otc-glucose-monitor-for-children XX Insulet presented new data from its STRIVE and EVOLUTION 3 studies showing improved glucose control with its next-generation Omnipod 6. That's , the company's upcoming hybrid closed-loop system for people with type 1 and type 2 diabetes. The main difference between the Omnipod 6 and Insulet's current Omnipod 5 patch pumps is that the new system has a lower glucose target of 100 mg/dL and better Bluetooth connectivity Insulet also shared progress on a fully closed-loop system designed specifically for type 2 diabetes. It  does not require carb-counting or insulin bolusing ahead of meals. Physicians also don't need to program the starting settings.   XX Abbott shared new research highlighting challenges in identifying and managing diabetic ketoacidosis (DKA). The studies coincide with the company's development of Libre Duo, a dual glucose-ketone sensor that continuously tracks both measurements. Abbott reported that DKA can be difficult to recognize when patients first arrive at the hospital, based on data from more than 100,000 people. The company has submitted the dual sensor to the FDA and recently received CE Mark approval in Europe. More news from ADA including info from Dexcom, Sequel, Sensonics and the world loses a tireless T1D advocate.. that's all to come right after this. --   Back to the news.. XX   Dexcom announced its acquisition of Nutrisense, a company that combines continuous glucose monitoring with nutrition coaching and behavioral support. At ADA, the company also presented results from the CONNECT study showing significant A1C reductions and improved glucose control in people with type 2 diabetes not using insulin. The findings add to growing evidence supporting CGM use beyond intensive insulin therapy. We did an episode with CEO Jake Leach at ADA about these announcements as well as updates on G8, their hospital product and much more. XX Sequel Med Tech reported positive clinical results evaluating its twiist automated insulin delivery system in people with type 2 diabetes. The study showed improvements in A1C and time in range over 13 weeks XX Senseonics presented new real-world data supporting the performance of its Eversense 365 implantable CGM. The analysis included more than 12,000 sensors and demonstrated sustained accuracy and effectiveness in both open-loop and automated insulin delivery settings. Researchers also evaluated Eversense use with Sequel Med Tech's twiist system. The findings support broader use of long-term implantable CGM technology.   -- MiniMed used ADA 2026 to spotlight two recently cleared diabetes management systems. The MiniMed Flex pump offers a smaller, smartphone-controlled insulin pump option, while MiniMed Go combines the InPen smart insulin pen with Abbott's Instinct sensor. The products received FDA clearance earlier this year. XX Tandem Diabetes Care highlighted data supporting the use of its Control-IQ automated insulin delivery technology during pregnancy. Results from the CIRCUIT trial showed users spent approximately three additional hours per day in the recommended pregnancy glucose range compared with standard therapy. The findings helped support recent regulatory approvals for pregnancy use in both Europe and the United States. Tandem also expanded indications for adults with type 2 diabetes. XX Beta Bionics presented real-world data from the first three years of iLet Bionic Pancreas use. The company reported a 25% improvement in time in range among users, along with positive feedback from clinicians about simplified diabetes management. The iLet system requires only a user's weight to begin therapy and eliminates carbohydrate counting. Beta Bionics also highlighted growing access to near-real-time outcomes through its public data dashboard. XX MannKind presented new findings supporting its Afrezza inhaled insulin at ADA 2026. A post-hoc analysis of the INHALE-1 study found that pediatric users reported greater treatment satisfaction compared with those using rapid-acting injected insulin. The results come shortly after FDA approval expanded Afrezza's indication to include children. We did a bonus episode with one of the lead investigators of the study that lead to that approval. XX Adaptyx presented early clinical data supporting a wearable sensor that continuously measures cortisol levels. The device successfully tracked cortisol changes during both controlled testing and overnight monitoring in first-in-human studies. Company leaders say cortisol plays a major role in conditions including diabetes, hypertension, and depression. The technology uses synthetic DNA-based molecular switches to generate real-time readings.   XX Biolinq shared new clinical findings for its Shine continuous glucose monitoring system. The needle-free device combines glucose monitoring with activity and sleep tracking .The system received FDA clearance in 2025. They're also looking at measuring lactate through the sensor. XX Long-time T1D advocate Kent Schnakenberg died last week. Schnakenberg was known in his community for using his love of bicycling to raise awareness of Type 1 diabetes. He also advocated for improving the lives of those living with the disease. Inspired by his niece, Michelle, who was diagnosed with juvenile diabetes when she was 13 years old, since 2014 he has traveled around the country cycling thousands of miles, speaking to hundreds and hundreds of kids and raising Money. According to Schnakenberg's family, he suffered a head trauma incident in his home on Wednesday. I spoke to Kent years ago – I believe the first year of the podcast. A sad loss but wonderful to see so many tributes and memories posted on social media in the last few days. https://diabetes-connections.com/john-costik-co-creator-of-nightscout-team-schnak/ https://www.wibw.com/2026/06/12/team-schnak-founder-kent-schnakenberg-passes-away/ XX And finally. Alexander Zverev (ts-ver-uhv) won the French Open, his first Grand Slam title. He lives with type 1, he paused a couple of time to check his blood sugar. He was diagnosed at age 4 and partners with Medtronic. "Becoming a professional tennis player was always my dream," Zverev shared in an article posted by Medtronic. "Early on, I was told that competing at the highest level with diabetes was impossible — but my family and I refused to accept that. That's why I'm partnering with Medtronic Diabetes: I want every person with diabetes to feel empowered to live the life they want." He also has a foundation committed to children with type 1 diabetes. Among other things, the life-saving insulin and other essential drugs are provided – also in developing countries." https://www.mensjournal.com/news/alexander-zverev-diabetes-wins-french-open-2026-medical-condition

ADA 2026 delivered a massive wave of obesity and diabetes data, and in this episode of On The Pen, Dave Knapp (@manonthemounjaro) sits down witH ​⁠ to break down the molecules, clinical trials, weight loss results, and safety signals that could define the next generation of obesity and diabetes medicine.We dive deep into Survodutide, Mazdutide, UBT251, Berobenatide (MET-097), CagriSema, Zenagamtide (formerly Amycretin), Petrelintide, and so much more!From GLP-1/glucagon dual agonists to triple agonists targeting GLP-1, GIP, and glucagon, the obesity treatment landscape is becoming more competitive than ever. Which therapies showed the strongest weight loss? Which struggled with tolerability? And what do these results mean for patients living with obesity, type 2 diabetes, MASLD, sleep apnea, and other metabolic diseases?In this episode:✅ Survodutide obesity and liver fat reduction data✅ Mazdutide Phase 3 obesity and diabetes results✅ UBT251 triple agonist weight loss data✅ Berobenatide (MET-097) long-acting GLP-1 updates✅ CagriSema diabetes and obesity trial results✅ Zenagamtide (Amycretin) injectable and oral development✅ Petrelintide amylin agonist info✅ Future GLP-1, GIP, glucagon, and amylin therapiesThe future of obesity medicine is no longer just about who produces the most weight loss. It's about matching the right therapy to the right patient, improving tolerability, and addressing metabolic disease beyond the number on the scale.Read more obesity medicine news at obesity.news

Is retatrutide, the new triple agonist GLP-1, the next big thing in weight loss (or even rapid fat loss)?That depends on how the drug works, what the results are, the reality between the headlines and the evidence, and what happens to your weight when you stop.This episode breaks down retatrutide, the GLP-1, GIP, and glucagon triple agonist behind the largest weight loss numbers ever recorded in this class. It covers the Phase 2 obesity trial and the Phase 3 Triumph results, plus why cross-trial comparisons to semaglutide and tirzepatide deserve skepticism.We examine the body composition data (or lack thereof), and why a bigger number on the scale just amplifies the stakes for muscle mass, weight regain, and the off-ramp. Especially relevant for adults over 40 who are taking, considering, or planning to come off a GLP-1.Enroll in Eat More Lift Heavy, the 26-week coached program where adults over 40 build the nutrition and training skills to preserve muscle, lose fat, and manage their physique for life, including support for lifestyle changes needed while taking GLP-1s (and to come off them if desired).Timestamps:0:00 - Retatrutide and the biggest question for GLP-1 users 3:08 - How this new triple agonist works 4:46 - Phase 2 and Phase 3 weight loss numbers 5:38 - Cross-trial comparisons and their limits 6:23 - Fat, muscle, and what the trial did NOT measure 8:30 - Strength training over 40 and accelerated muscle loss 10:07 - Building the lifestyle (alongside using the drug) 14:10 - Resistance training and protein 16:00 - Rate of loss on a powerful drug like retatrutide 17:30 - The off-ramp when you stop 18:23 - Weight regain and body fat overshooting 22:03 - Retatrutide access and the gray market 24:11 - Bonus: 3-question test to keep your resultsEpisode Mentioned:Sometimes More Is More (The Sedentary Lifter Problem)

Can retatrutide finally be the breakthrough obesity treatment we've been waiting for? The answer is yes—and the data is stunning. In this episode I'm walking you through the biggest obesity medicine discovery from the ADA's 86th Scientific Session: retatrutide, a triple hormone receptor agonist showing weight loss results that rival bariatric surgery. You'll learn what makes retatrutide different from Wegovy and Zepbound, the stunning results from the Triumph 1 trial, what the side effects actually look like, and when this medication will finally be available. Weight loss medications are evolving faster than ever. But what you really need to know is what these results mean for your health. Listen now! Episode Highlights: Retatrutide is a triple hormone agonist that targets GLP-1, GIP, and glucagon receptors Participants lost an average of 28.3% of their body weight in 80 weeks Two-thirds of participants achieved a normal BMI—moved from obese to healthy weight Nearly everyone with prediabetes reversed it and returned to normal blood sugar Over 70% reduction in knee osteoarthritis pain and 60% reduction in sleep apnea severity The highest discontinuation rate due to side effects was only 11%—mainly GI issues Retatrutide is not yet FDA approved but anticipated to launch early 2027 Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Timestamps : 00:00 — Intro — Welcome to the Holistic Kids Show 00:20 —  The Childhood Obesity Crisis: The Numbers 01:14 — Guest Introduction: Ashley Koff, RD 02:12 — Ashley's Personal Story & What Drove Her Mission 04:34 — Rethinking Weight: It's a Signal, Not a Sentence 05:15 — Introducing Your Best Shot & Weight Health 06:07 — Understanding Hormones: GLP-1, GIP, CCK & PYY Explained Simply 08:15 — How Gut Hormones Control Blood Sugar, Appetite & Bone Health 10:16 — The Gut-Hormone Connection: Why Your Microbiome Matters 11:05 — Can Kids Take GLP-1 Hormones? 11:25 — Ozempic, Wegovy & GLP-1 Medications Explained 13:40 — GLP-1 Medications Approved for Kids 10+ — What Parents Must Know 15:28 — 3 Daily Habits to Naturally Balance Your Hormones 17:21 — Habit #2: Eat Like a Race Car — Fueling at the Right Times 18:04 — Habit #3: Move After Every Meal — Why 7 Minutes Matters 22:03 — "Better, Not Perfect" — What That Really Means for Teens 25:00 — The One Nutrition Rule Every Kid Should Know 29:49 — Where to Find Ashley Koff & Her Resources One in five US children lives with obesity — but are we asking the right questions? In this powerful episode, the Holistic Kids crew sits down with Ashley Koff, RD, USA Today bestselling author of Your Best Shot and a leading weight health practitioner with over 25 years of experience. Ashley flips the script on how we talk about weight with kids — moving away from diets, BMI, and body shame, and toward understanding what the body is actually telling us. She explains how hormones like GLP-1, GIP, and PYY are made in the gut lining, why antibiotics and medications can disrupt them for years, and what that means for growing bodies. The conversation also tackles the rising use of GLP-1 medications (like Ozempic and Wegovy) in kids as young as 10 — what the research says, what parents and teens should know, and why these medications are a tool, not a solution on their own. In this episode, you'll learn: Why weight is a signal, not a sentence What GLP-1, GIP, and gut hormones actually do — explained simply How antibiotics and medications affect your hormones for years The truth about GLP-1 medications for kids and teens 3 daily habits to naturally support hormone balance Why BMI is a flawed measure — and what to look at instead The "race car" nutrition approach that keeps your body running better What "better, not perfect" really means for teenagers Guest: Ashley Koff, RD — Founder of The Better Nutrition Program, author of Your Best Shot, recognized by CNN as one of the Top 100 Health Makers.

De tweede dag Lauwersmeer staat in het teken van hard werken voor je waarnemingen. We gaan namelijk een geheel rondje Lauwersmeer fietsen en dat is maar liefst 50km. Maar de sfeer zat er direct goed in, want we waren nog geen 20 minuten onderweg of we werden getrakteerd op het prachtige geluid van de wielewaal. En dan is het zoeken geblazen, want ook al is de vogel knal geel met zwart hij blijft verdomde lastig. Een typisch gevalletje; je hoort hem wel, maar zit hem niet. Maar er staan nog meer knallers op het dagprogramma. Zo moet Gip de Blauwborst nog en de mooiste vogel van Nederland: het baardmannetje. Kortom er is genoeg te beleven met als kers op de taart een vogel die menig deelnemer nog niet op zijn of haar lijst had. Arjan is overigens weer zo fanatiek dat hij zelfs de groep geen koffiebreak gunt, maar gelukkig steekt mooi-weer-vogelaar Gisbert daar een stokje voor. Het moet leuk blijven. En dan nog iets anders: De Vogelspotcast bestaat 5 jaar en dat vieren we met prijzen. Hiep hiep Hoera! Om deze prijzen te winnen vragen we ± 5 minuten van je tijd om een vragenlijst in te vullen. We zouden graaag beter weten wat jullie leuk vinden en wat misschien beter of anders kan. Met jouw antwoorden help je ons om de Vogelspotcast te verbeteren én om meer mensen dichter bij vogels te brengen. Je vindt de vragen lijst op www.vogelspotcast.com/vragenlijst - Alvast heel erg bedankt voor jouw hulp!Ps. Al ruim 700 mensen hebben de vragenlijst al ingevuld! Echt geweldig. Onze dank is gigantisch. Partnerships:1) SNP Natuurreizen gemaakt. Wil je ook op Vogelvakantie. Klik HIER voor hun aanbod2) Vogelbescherming Nederland. Het gaat niet goed met de Steenuil en dat is niet best. Daarom halen we met Gip's Big Year zo veel mogelijk geld op om hier wat aan te doen. Jouw donatie zou enorm helpen. Ga naar www.vogelbescherming.nl/bigyear om te doneren. Alvast heel erg bedankt voor uw steun.Zie het privacybeleid op https://art19.com/privacy en de privacyverklaring van Californië op https://art19.com/privacy#do-not-sell-my-info.

Dr. Spencer and Karl Nadolsky sit down with David W, a nurse practitioner and one of the actual patients enrolled in the Triumph 1 retatrutide phase 3 trial, to break down the data that was just presented at the American Diabetes Association conference and explain why everyone in obesity medicine is paying very close attention. In this episode they cover what retatrutide actually is and why adding glucagon agonism to the GLP-1 and GIP dual agonism of tirzepatide creates a meaningfully different drug with direct effects on liver lipid metabolism, insulin sensitivity, blood pressure, and fat catabolism that you do not see with semaglutide or tirzepatide alone, what David's personal experience in the 12 milligram arm looked like from dose escalation through steady state including the GI side effects that faded by month seven and the heartburn that a low dose PPI fixed quickly, how David went from 240 pounds and a BMI of 35 down to 167 pounds by the end of the trial representing roughly 30 percent weight loss which is right at the trial average, what the Triumph 1 obesity trial found at 80 weeks with the nine and 12 milligram doses delivering nearly 26 and 28 percent average weight loss respectively and almost half of patients on the highest dose losing 30 percent or more, why the 104 week extension data showing patients who stayed on 12 milligrams reaching 30.3 percent average weight loss is being compared to bariatric surgery outcomes, what the Transcend type 2 diabetes trial showed with average A1C dropping to 5.9 percent on the 12 milligram dose in patients who were on no other diabetes medication, why the 41 percent triglyceride reduction and 20 percent LDL reduction are particularly interesting given that the mechanism appears to involve multiple pathways in the liver that tirzepatide and semaglutide do not touch, what the 70 percent reduction in WOMAC knee arthritis pain scores and 60 percent reduction in sleep apnea events mean for patients who have been told their only option is surgery, how Spencer plans to use retatrutide clinically once it is approved and which patients he thinks are the right candidates, why the gray market research peptide version currently circulating is something both doctors strongly advise against, and what Triumph 2 and Triumph 3 are measuring and when that data is expected. The Docs Who Lift podcast distills and simplifies the complexities of exercise, medicine, and weight loss. Subscribe so you never miss an episode. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

We zitten inmiddels in de zesde maand van Gip's Big Year en er staan nu 210 soorten op zijn lijst. Je zou zeggen dat hij goed op schema ligt, maar zo werkt het natuurlijk niet helemaal. Een vogel per dag is in het begin relatief makkelijk, maar het glazen plafond nadert snel in de vogelwereld. Want waar vind je zo snel eigenlijk zeldzaamheden als een woudaap, grauwe kiekendief of smelleken? Gelukkig maken we dit jaar twee buitenlandreizen met SNP Natuurreizen die flink zoden aan de dijk zetten. En in Nederland is ook nog genoeg te vinden, waren we het al snel over eens met hen. Daarom gaan we samen met de Dwaalgasten op Nederlandse vogelreis naar het befaamde Lauwersmeergebied om daar 4 dagen met elkaar te vogelen. De weergoden zijn ons goed gestemd en er zit volgens Arjan een hele bijzondere vogel op ons te wachten!En dan nog iets anders: De Vogelspotcast bestaat 5 jaar en dat vieren we met prijzen. Hiep hiep Hoera! Om deze prijzen te winnen vragen we ± 5 minuten van je tijd om een vragenlijst in te vullen. We zouden graaag beter weten wat jullie leuk vinden en wat misschien beter of anders kan. Met jouw antwoorden help je ons om de Vogelspotcast te verbeteren én om meer mensen dichter bij vogels te brengen. Je vindt de vragen lijst op www.vogelspotcast.com/vragenlijst - Alvast heel erg bedankt voor jouw hulp!Partnerships:1) SNP Natuurreizen gemaakt. Wil je ook op Vogelvakantie. Klik HIER voor hun aanbod2) Vogelbescherming Nederland. Het gaat niet goed met de Steenuil en dat is niet best. Daarom halen we met Gip's Big Year zo veel mogelijk geld op om hier wat aan te doen. Jouw donatie zou enorm helpen. Ga naar www.vogelbescherming.nl/bigyear om te doneren. Alvast heel erg bedankt voor uw steun.Zie het privacybeleid op https://art19.com/privacy en de privacyverklaring van Californië op https://art19.com/privacy#do-not-sell-my-info.

Description:  How do GLP-1 receptor agonists or GIP agonists work and what is the impact for my psoriatic disease? Hear dermatologist Dr. Ronald Prussick and cardio-immunologist Dr. Brittany Weber answer such questions and more.           Join host Archie Franklin as he takes a deep dive into the use of GLP-1 receptor agonists and GIP agonists and the convergence of systemic inflammation related to psoriatic disease with renowned dermatologist and Vice Chair of the NPF Medical Board, Dr. Ronald Prussick from Washington Dermatology Center in Rockville and Frederick, MD, and, cardio-immunologist Dr. Brittany Weber, Director of the Cardio-Rheumatology/ Cardio-Dermatology Program at the University of Texas Southwestern. Learn more about the use of incretin hormones, the impact of weight management on psoriatic disease, metabolic and cardiovascular risk, as well as results from the TOGETHER-Pso and TOGETHER-PsA clinical trials.  This episode addresses the actions of incretin hormones (GLP-1 receptor agonist and GIP agonist) and how such use may be beneficial in the management of inflammation related to psoriasis and psoriatic arthritis.  Thank you to Lilly for their support of this program activity.  Timestamps: (0:00)  Intro to Psoriasis Uncovered & guest welcome dermatologist Dr. Ronald Prussick and cardio-immunologist Dr. Brittany Weber.  (1:35)  What are incretin hormones and how GLP-1 or GIP receptor agonists (RA) inhibit appetite to initiate weight loss. (3:29)  Why GLP-1 RAs are of interest in the management of psoriasis and psoriatic arthritis. (5:23)  The metabolic, cardiovascular, and psoriatic disease convergence. (7:19)  Will reduction of inflammation impact cardiovascular risk? (10:59) Treatment challenges associated with having psoriatic disease and being overweight or obese. (13:45)  Key points around the use of GLP-1 receptor agonists when managing psoriasis and psoriatic arthritis. (17:06)  Results of the TOGETHER-PsO and TOGETHER-PsA phase 3 clinical trials combining use of an IL-17 inhibitor and a GIP and GLP-1                receptor agonist therapy. (19:07)  Having the conversation of adding a GLP-1 RA medication to a treatment regimen. (22:40)  The paradigm shift of GLP-1 receptor agonists and the impact they can have on shared inflammatory pathways. Key Takeaways: ·       Glucagon-like peptide-1 (GLP-1) receptor agonists and glucose-dependent insulinotropic polypeptide (GIP) agonists are two incretin hormones that assist in managing excess body weight -- which as a result can be helpful in managing inflammation in the body.   ·       Psoriasis isn't just a skin and joint disease. It's a complex network of systemic inflammation with shared inflammatory pathways that worsens with increased weight impacting the severity of the disease, and accelerates the risk of metabolic dysfunction, and cardiovascular disease.   ·       The best outcomes occur as a result of multidisciplinary collaboration to address the impact of excess weight and systemic inflammation. If you are struggling to lose weight with diet and exercise, speak with your medical team about your options including the use of GLP-1 or GIP agonists.   Guest Bios: Renowned dermatologist Ronald Prussick, M.D., Medical Director of the Washington Dermatology Center in Rockville and Fredrick, Maryland, specializes in the treatment of psoriasis along with other diseases of the skin, hair, and nails. Dr. Prussick is also a Clinical Associate Professor in Dermatology at George Washington University in Washington, D.C.. Dr. Prussick has a research interest in the impact of diet on psoriatic disease and metabolic health, first becoming interested after being involved in Dr. Joel Gelfand and Dr. Nehal Mehta's work in vascular inflammation trials using FDG-PET/CT scans to view systemic and cardiovascular inflammation associated with psoriatic disease. Dr. Prussick has since participated in the development of the 2018 Dietary Recommendations for Adults with Psoriasis or Psoriatic Arthritis and more recently the position statement "GLP-1 Receptor Agonists in Psoriasis: A Primer from the National Psoriasis Foundation Medical Board". Dr. Prussick is Vice Chair of the NPF Medical Board which provides clinical direction, treatment guidance, and education oversight to the organization and its Executive leaders.  Brittany Weber, M.D., Ph.D. is a cardio-immunologist who is the Director of the Cardio-Rheumatology/ Cardio-Dermatology Program at the University of Texas Southwestern. She is also a member of the Division of Cardiology, a clinical investigator, and imaging specialist. Dr. Weber's research integrates advanced imaging, molecular biology, clinical trials, and population health to understand how systemic inflammation and immune deregulation drives cardiovascular dysfunction. Prior to joining UT Southwestern in 2025, Dr. Weber served on the faculty at Harvard Medical School and was the Director of the Cardio-Rheumatology Clinic at Brigham and Women's Hospital, a nationally recognized clinic addressing inflammation-related heart disease through collaborative, patient centered care. Dr. Weber is also an author on the position statement "GLP-1 Receptor Agonists in Psoriasis: A Primer from the National Psoriasis Foundation Medical Board". Resources: "The Metabolic Collison and How You Can Take Control with Psoriatic Disease" podcast episode with dermatologist Dr. Ronald Prussick and registered dietitian Danielle Cahalan   "NPF Medical Board Issues GLP-1 Primer for Dermatologists" Press Release "Finding My Path to Managing Psoriatic Disease and Excess Weight" podcast episode featuring dermatologist Dr. Erin Boh, patient advocate Brian Lehrschal, and moderator Jennifer Bomberger. 

Tirzepatide, marketed as Zepbound, mimics the action of GLP-1 and GIP, two hormones naturally released by your gut. These hormones are critical in regulating appetite and how much food you consume. By enhancing the feeling of fullness and reducing hunger, tirzepatide helps support weight loss. Read the Full Episode Transcript: https://pepties.com/common-questions-of-tirzepatide/ Related Links/Products Mentioned: Peptide Podcast Partners Page https://pepties.com/partners/ Buy Peptides online at BioLongevity Labs: Use our link and enter COUPON CODE: PEPTIDEPODCAST  at checkout to receive 15% off your total order:  https://go.biolongevitylabs.com/SH5C Momentous Supplements (we use Creatine, Vital Aminos, Whey Protein) https://crrnt.app/MOME/OqGQOxGA LMNT – More Salt, Not Less.  https://elementallabs.refr.cc/default/u/johnjavit Thorne Supplements (we use Omega-3 with CoQ10, Red Yeast Rice, Zinc) https://get.aspr.app/SH1KvW Organifi Creatine and Shilajit Gummies http://rwrd.io/rlbkajm?c MitoZen (methylene blue for Cognitive Function, Anti-Aging, Mental Clarity) https://www.mitozen.com/ref/cnlwiztypt/ For skin and hair health (Copper Tripeptide-1)  Visit Luminose by Entera for an exclusive offer for Peptide Podcast listeners!  ** Promo code PEPTIDEPODCAST at checkout for 10% off an order or 10% off the first month of a subscribe-and-save. ** https://www.enteraskincare.com/?rfsn=8906839.f93c72 NAD+ Push Patch: https://www.pushpatch.com/

This episode is sponsored by AquaTru. AquaTru - Go to https://AquaTru.com/ now for 20% off (your purifier) using promo code FLIPPING50. AquaTru even comes with a 30-day best-tasting water guarantee. Other Episodes You Might Like: Previous Episode - Roadblocks Women Experience When They're Doing "All The Things" Next Episode - Rebounding vs Whole Body Vibration After 50 Which? When? Worth It? More Like This - GLP-1 Medications for Weight Loss: A 42-Year Fitness Professional's Honest Take Resources: Don't know where to start? Book your Discovery Call with Debra. Leave this session with insight into exactly what to do right now to make small changes, smart decisions about your exercise time and energy. Use Flipping 50 Scorecard & Guide to measure what matters with an easy at-home self-assessment test you can do in minutes. Optimal weight health in menopause isn't about eating less or exercising more—it's about finally understanding what your body has been trying to tell you.  If you've been frustrated with stubborn weight gain, low energy, or conflicting advice, this conversation will feel like a reset. We're breaking down the truth about GLP-1, gut health, hormones, and why your results may have stalled despite doing everything “right.”  This episode shifts the focus from quick fixes to a personalized strategy that actually works with your body, not against it. Because optimal weight health in menopause starts when you stop guessing and start listening. My Guest: Ashley Koff, RD, is an acclaimed weight-health expert, “Hollywood's Leading Dietitian” featured in InStyle and practitioner for more than 25 years. Koff is leading a transformative movement in personalized nutrition, turning “better, not perfect” choices into practical, sustainable strategies that deliver real outcomes.  She is the founder of The Better Nutrition Program (BNP) and author of USA Today bestselling Your Best Shot, which introduces weight-health hormones (GLP-1, GIP, CCK, PYY) as the regulators of weight health, offering the first-ever assessment of their function and a personalized optimization system—shot or not. Questions We Answer in This Episode: [00:02:35] What does optimal weight management really mean in menopause? [00:07:39] Are you ahead of your time and getting pushback for your approach? [00:03:17] What are GLP-1 hormones and why do they matter? [00:25:11] Is the fear valid that GLP-1 stops your body from producing its own hormones? [00:29:49] Should we be talking about something more important than muscle loss first? [00:31:21] How does cortisol actually influence weight health in menopause? How can women address the connection between cortisol, GLP-1, and weight? If this episode made you flip your workout routine — share it!

Dr. Spencer Nadolsky and Karl sit down with Dr. Adam Auton, geneticist at 23andMe, to break down a brand new paper using data from over 27,000 people that identified specific genetic variants linked to how well GLP-1 medications work and how likely someone is to experience side effects. 23andMe has over 11 million people in their research database and used voluntary survey data on medication use, dosage, duration, weight loss, and side effects to match against genetic profiles at scale, making this one of the most powerful datasets anyone has brought to this question. In this episode they cover how genome-wide association studies work and why scanning 600,000 genetic variants at once lets researchers find signals they never could have predicted in advance, why the first signal that jumped out of the data was a variant right in the GLP-1 receptor itself and why that was the moment the team knew they were on the right track, why the same variant that predicts better efficacy also predicts a higher risk of side effects and what that tells us about how the drug is being processed, why tirzepatide users showed a separate signal in the GIP receptor that modulates side effects rather than weight loss, why carrying both variants could make someone 14 times more likely to experience side effects on tirzepatide, why genetics explains roughly 10 percent of weight loss variation and what the other 90 percent looks like, why women tend to respond better than men and why diabetics tend to respond less well, what the future of this research looks like including who regains weight after stopping and whether those patterns are genetically predictable, and why heritability is a statistical measure that gets badly misunderstood even by clinicians. The Docs Who Lift podcast distills and simplifies the complexities of exercise, medicine, and weight loss. Subscribe so you never miss an episode. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Today, I'm pulling together some of the most impactful conversations from the last three months on the Podcast. From breaking down the pitfalls of trendy weight loss drugs to uncovering silent heart health risks, and exploring how mitochondrial transplants and trauma healing are rewriting the story of resilience, these moments have truly shifted my perspective on what it means to pursue lasting wellness. Here are the full episodes: #401: Personalization Is EVERYTHING: The New Science of Weight Health, GLP-1s, and Building Lasting Longevity With Ashley Koff #414: Drop Dead Healthy? Why "Fit" Women & Men Still Have Fatal Heart Attacks! l Dr. Regina Druz #419: Origin Of Disease Is Hiding In Your Cells! Doctor Reveals How To Fix It Now l Dr. Natalie Yivgi-Ohana #421: Why You Can't Hack Longevity Until You Heal Hidden Stored Trauma! l Dr. Aimie Apigian #417: Feeling Depressed? Watch This First (It Might Not Be What You Think) l Dr. Cynthia Keller l Ep  Episode Timestamps: Welcome and quarterly recap intro ... 00:00:00 Longevity is about pattern recognition, not single breakthroughs ... 00:00:41 GLP-1s require personalization, not a one-size-fits-all approach ... 00:04:25 GLP-1 hormone assessment and individualized plans ... 00:06:03 Delayed/suppressed GLP-1 function needs lifestyle changes ... 00:08:04 GLP-1 agonists enable, but don't replace, foundational health tweaks ... 00:09:06 Heart health: sick fat disease, inflammation and cardiac risk ... 00:12:30 GLP-1 and GIP peptides have powerful anti-inflammatory effects ... 00:15:35 Menopause amplifies pre-existing heart/metabolic risks ... 00:18:22 Mitochondrial transplants: emerging therapy for rare diseases ... 00:24:04 Every disease linked to—or helped by—mitochondrial function ... 00:27:00 Trauma healing is phased; start with the gentle approach ... 00:31:21 Chronic survival state rewires the nervous system ... 00:40:02 Covid's gut impact can trigger mood issues, fixed with key nutrients ... 00:50:00 Our Amazing Sponsors: Mitopure Gummies by Timeline - These clinically researched gummies support mitophagy to help renew your mitochondria and boost cellular energy, giving you a stronger biological foundation for resilience—visit timeline.com/nat20 to get 20% off. Quantum Upgrade - Supports nervous system balance without wearables or apps—just effortless, 24/7 quantum energy streaming. With 21+ studies showing measurable improvements in stress and cellular function, it's easy to try for yourself. Visit quantumupgrade.io/NAT and use code NAT15 to start the free 15 day trial. Daily Gut Detox by Just Thrive Health – A gentle, science-backed detox powered by clinically proven immunoglobulins that bind and remove toxins while supporting your gut, immune system, and digestion—without harsh flushing or discomfort. Visit JustThriveHealth.com/NAT20 and use code NAT20 for 20% off your order, risk-free. Nat's Links: YouTube Channel Join My Membership Community Sign up for My Newsletter Instagram Dr. Bill Lawrence Episode

Join us as we review and appraise recent practice-changing articles. In this episode, we cover the latest in GLP-1s and GIP agonists for CVD, Type 2 Diabetes, and Obesity, valacyclovir to treat Alzheimer's, weight regain patterns after medication-induced weight loss, and a deep dive into the data behind deprescribing – and behavioral science to increase deprescribing behavior.  Fill your brain hole with a delicious stack of hotcakes! Featuring Paul Williams (@PaulNWilliamz), Alex Chaitoff (@alexchaitoff), Nora Taranto (@norataranto), & Matt Watto (@doctorwatto).Claim CME for this episode at curbsiders.vcuhealth.org!Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CMECredits Written and Hosted by: Nora Taranto MD, MSCE; Alexander Chaitoff MD, MPH; Paul Williams, MD, FACP,, & Matthew Watto MD, FACP Cover Art: Nora Taranto MD, MSCE Reviewer: Sai S Achi MD, MBA, FACP Technical Production: Pod Paste Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Show Segments Intro, disclaimer GLP-1 + GIPs vs GLP-1s for patients with T2DM and Obesity – SURPASS-CVOT  Weight Regain after Weight loss  VALAD – Valacyclovir in patients with early Alzheimer's  Nudges to increase Deprescribing  Outro Sponsor: MedStudy Qbank Study less. Remember more. Pass confidently.Medstudy.com/CurbsidersCURB15 for 15% offSponsor: FIGSWe've teamed up with FIGS, and now Curbsiders listeners can get 15% off at Wearfigs.com with code FIGSRX. Sponsor: QuinceRight now, go to Quince.com/curb for free shipping and 365-day returns. Sponsor: A Dangerous DiagnosisTo get 20% off use DIAGNOSIS20 at www.penguinrandomhouse.com/books/808848/a-dangerous-diagnosis-by-shantanu-rai/paperback/